

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email <a href="mailto:info.bmjopen@bmj.com">info.bmjopen@bmj.com</a>

### **BMJ Open**

### Article Placement Order in Rheumatology Journals: A Content Analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-034550
Article Type:	Original research
Date Submitted by the Author:	25-Sep-2019
Complete List of Authors:	Stewart, Sarah; The University of Auckland, Medicine Gamble, Greg; University of Auckland, Department of Medicine Grey, Andrew; University of Auckland Dalbeth, Nicola; University of Auckland,
Keywords:	publication, bias, RHEUMATOLOGY

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

#### **Article Placement Order in Rheumatology Journals: A Content Analysis**

Sarah Stewart<sup>1</sup>, PhD

Greg Gamble<sup>1</sup>, PhD

Andrew Grey<sup>1</sup>, MD

Nicola Dalbeth<sup>1, 2</sup>, MD

<sup>1</sup> School of Medicine, The University of Auckland, 85 Park Road, Grafton, Auckland 1062,

New Zealand

<sup>2</sup> Corresponding author: School of Medicine, The University of Auckland, 85 Park Road,

Grafton, Auckland 1062, New Zealand; n.dalbeth@auckland.ac.nz; +64 9 923 2568

Word count: 3208

#### **Abstract**

**Objectives.** To analyse variables associated with article placement order in serial rheumatology journals.

**Design.** A content analysis of original articles published in seven rheumatology journals from 2013-2018.

**Methods**. The following data were extracted from 6,787 articles: order number of article in issue, gender of first and last author, geographical region, industry funding, and disease category. Cumulative density function plots were used to determine whether article placement distribution was different from the expected distribution. Odds ratios for articles published in the first three places of an issue compared with the last three places were calculated. Altmetric score and downloads were meta-analysed.

**Results**. Article placement order did not associate with author gender, geographical region or funding source, but was associated with disease category. Articles about rheumatoid arthritis were more likely to be ordered at the front of issues (P<0.001). Articles about crystal arthritis, systemic lupus erythematosus, vasculitis, pain syndromes and pediatric rheumatic diseases were more likely to be ordered at the end of issues (all P<0.001). Association of article placement order with disease category was observed only in journals with tables of contents grouped by disease. Articles ordered in the first three places had higher Altmetric and download rates, than articles in the last three places.

**Conclusions.** Author gender, geographical region, or funding source do not influence article placement order in serial rheumatology journals. However, bias for certain disease categories is reflected in article placement order. Editorial decisions about article placement order can influence the prominence of diseases.

Keywords: publication, bias, rheumatology



#### Strengths and limitations of the study

- This is the first study to assess the relationship of article placement order in serial medical
  journals with author gender, geographical region of affiliated institution, industry funding
  or disease category.
- This content analysis included 6,787 articles from general rheumatology journals.
- This study also analysed the impact of article placement order on research prominence, including Altmetric scores and download rate.
- This analysis did not explore other factors that may have contributed to article placement order such as the originality of the study findings or the presence of "star" authors.

#### INTRODUCTION

The strong preference for items ordered first, and the important effect of list order on choice, is well-recognised in consumer-based research.[1-3] In online searches for health information, 97% of selected links were displayed in the first 10 results, while only 2% were from the second or following pages.[4] For online academic repositories, earlier listed articles were downloaded more frequently than later listed articles.[5] These primacy effects, which increase when lists are longer,[6] may occur because earlier items, or those at the top of tables of contents, are more visible and more likely to be seen and read.[5]

In academic publishing, the ordering of articles within a journal issue also affects the prominence achieved by that research. Earlier listed articles received more citations over a 25 year period in a single journal.[7] The impact of ordering was also evident in an analysis of emails sent to subscribers disseminating recent research papers listed in random order; with the first paper having a 33% increase in views, 29% increase in downloads and 27% increase in citations, regardless of research quality.[8]

A number of systemic biases have been reported in academic publishing. These include preferential lead and senior authorship of men,[9, 10] higher acceptance rates for articles from the US and Europe,[9, 11] preferential publication of industry-funded research,[12] and disease privileging, wherein particular diseases receive preferential research funding and publication.[13-15] It is unknown whether these systemic biases are reflected in article placement order within medical journals. We analysed serial rheumatology journals for relationships between article placement order and gender of the lead and senior authors, geographical region of the affiliated institution, industry sponsorship, and disease category.

#### **METHODS**

#### Patient and public involvement

There was no patient or public involvement in the design, or conduct, or reporting, of this research.

#### Identification of journals and articles for inclusion

This was a cross-sectional content analysis of original articles published in general rheumatology journals. Journals were included if they produced regular issues, reported original research and had 2016 Thomas Reuters Impact Factors of > 3.0. Journals were excluded if they published review articles only, were disease-specific (e.g. *Lupus*, *Osteoarthritis and Cartilage*) or produced no issues. The following seven general rheumatology journals met the above criteria and were included: *Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Arthritis Care & Research, Seminars in Arthritis and Rheumatism, Rheumatology, Journal of Rheumatology, and Joint Bone Spine. Characteristics of the included journals are shown in Supplementary Table 1.* 

All original articles published in the included journals in a five-year period from June 2013 to June 2018 were included in the analysis. To be included, articles could be full or concise reports, and report on original basic science or clinical research, including systematic reviews and meta-analyses. Articles were excluded if they were from a disease-specific thematic issue or supplement, were narrative reviews, recommendations, guidelines, letters, or meeting reports.

#### **Data extraction**

Data extraction was undertaken between June and December 2018. The following information was extracted for each included article: order number of article in the issue, gender of lead (first) author; gender of senior (final) author; geographical region of affiliated institution (for the first author); any industry sponsorship (industry-funded and initiated/industry-funded and investigator-initiated/not industry-funded); and, if available, the Altmetric score and number of downloads. The number of citations was not assessed because of the short time period between publication and data extraction. If author gender could not be determined by first name or by an internet search of the author's affiliated institution profile page, then the author's first name was entered into https://api.genderize.io/?name= which returns the gender and probability of certainty. Probabilities < 0.5 were labelled as "unknown" and not included in the gender-related analysis. If articles were authored by a single author, then this author's gender was entered under first author. Funding was assessed by review of funding statements, disclosures and author affiliations. Industry-funded studies were categorized as industry-funded and industry-initiated, or industry-funded and investigator-initiated, based on these statements. Studies with no evidence of industry funding were categorized as not industry-funded.

Articles were coded according to the following 13 disease categories: ankylosing spondylitis and other spondyloarthropathy, crystal arthritis, osteoarthritis, miscellaneous rheumatic disease, pediatric rheumatology, pain syndromes, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis/scleroderma, other connective tissue disorders, vasculitis, and not disease-specific. The title of each article was used to determine the disease category. If there was uncertainty about the disease category from the title, then the abstract and/or full paper were reviewed.

To ensure standardisation in data extraction, two authors (SS, ND) independently reviewed eligible papers from ten randomly selected issues. A total of 208 articles were reviewed, with

kappas of 1.00 for author gender, geographic region and industry funding, while disease category had a kappa of 0.84 (86.1% agreement (95% confidence interval (CI) 81.0%, 90.5%)). All disease category disagreements were discussed to reach a consensus and a set of rules for categorising was established. The exercise was then repeated in which the two authors reviewed disease categories in a further five randomly selected issues totalling 85 articles, with a kappa of 0.99 (98.8% agreement (95% CI 94.3%, 99.9%)) for disease category. A single reviewer (SS) then independently extracted the data.

#### **Data analysis**

The primary analyses assessed the relationships between article placement order and: gender of first authors, gender of last authors, geographical region (North America vs. Europe vs. Other), industry funding categories (industry-funded and initiated vs. industry-funded and investigator-initiated vs. not industry-funded), and disease categories. In order to identify whether these factors were associated with article placement order within journal issues with different numbers of articles, each article within each issue was assigned a standard article placement index (SAPI), which was defined as the order of the article in the issue/total number of articles in the issue. For example, the first article in an issue of 21 articles was given an SAPI of 1/21 = 0.0476 and the last article 21/21 = 1. Cumulative distribution functions (CDF) were analysed to determine the associations between article placement order and author gender, geographical region industry funding and disease category. A uniform distribution would be expected if there was no association with article placement order: skewed deviations from the expected uniform distribution would support an association with article placement order. To test whether the distribution of SAPIs were different between author genders, geographical regions, and industry funding categories, two-sample

Kolmogorov-Smirnov Z tests were conducted. Effect sizes (*D*) were computed with values ranging from 0 (no difference in distribution of SAPI between comparisons) to 1 (large difference in distribution of SAPI between comparisons). To determine whether the distribution of SAPIs for each disease category was different from a uniform distribution CDF (expected distribution if no bias reflected in article placement order), the area under the curve (AUC) of the observed CDF and uniform distribution CDF were each calculated using a trapezoidal method and the difference between these estimated for each of the 13 disease categories. Mean differences between the observed CDF and the uniform distribution CDF were computed from bootstrapped samples (500 replicates, sampled with replacement) and 95% confidence intervals estimated as the 2.5th and 97.5th percentile of the bootstrap distribution. P-values were calculated for each disease category from these confidence intervals using the method of Altman and Bland.[16]

A secondary analysis was undertaken to further explore article placement order, in which mid-P exact P-values were computed to compare the proportion of articles appearing in at least one of the first three places of an issue compared to at least one of the last three places of an issue for genders of first and last authors, geographical region, industry funding category, and each disease category. Odds ratios (OR) and their 95% CIs were also computed for articles in the first three places vs. last three places of an issue.

As some journals presented their content grouped by disease category, additional analyses were undertaken to determine whether article placement order of disease categories was different between journals which presented content grouped by disease category vs. journals without disease category content grouping. This was tested statistically using CDF plots of SAPI distributions, two-sample Kolmogorov Smirnov Z tests and effect sizes (D) as described above.

Finally, to determine the impact of article placement order on Altmetric scores and article download rates (as available), meta-analyses were used to determine differences in the means for each variable between the first and last three articles in journal issues. Altmetric scores were provided by *Arthritis & Rheumatology, Annals of the Rheumatic Diseases*, *Rheumatology* and *Arthritis Care & Research. Annals of the Rheumatic Diseases*, *Rheumatology* and *The Journal of Rheumatology* had article download data available, but for the latter two journals, the data were available in only the 6 months prior to data extraction. Therefore, analyses of article downloads were undertaken for *Annals of the Rheumatic Diseases* only. For Altmetric scores, which generally do not change over time, mean scores were calculated by total Altmetric scores/total number of articles. For downloads, which are time dependent, rates were calculated by total number of downloads/total article-years from time of publication to time of data extraction. These analyses were undertaken within disease categories, adjusted by journal, as appropriate, and weighted using the inverse-variance method. Random effects models were used for all 1² values > 0%.

All analyses were performed in SPSS (v25 IBM Corp), SAS v9.4 (SAS Institute Inc, Cary, NC) and openepi.com (v3.01). All tests were two-tailed and false discovery rate (FDR)-adjusted P values[17] were computed for all analyses with an alpha level of < 0.05 considered significant.

#### **RESULTS**

#### **Characteristics of included articles**

A total of 6,787 articles were included. First authors were male in 3250 (47.9%) articles, female in 3517 (51.8%) articles and unknown in 20 (0.3%) articles. Last authors were male in 4412 (65.0%) articles, female in 2359 (34.8%) articles and unknown/not applicable in 16

(0.2%) articles. 596 (8.8%) articles were industry-funded and initiated, 640 (9.4%) were industry-funded and investigator-initiated, and 5551 (81.8%) were not industry-funded. The geographical region was North America in 2177 (32.1%) articles, Europe in 3486 (51.4%) articles, and Other in 1124 (16.6%) articles. Disease categories were rheumatoid arthritis (n = 1946, 28.7%), osteoarthritis (n = 773, 11.4%), systemic lupus erythematosus (n = 642, 9.5%), ankylosing spondylitis (n = 496, 7.3%), pediatric rheumatology (n = 443, 6.5%), systemic sclerosis (n = 433, 6.4%), not disease-specific (n = 422, 6.2%), vasculitis (n = 362, 5.3%), other connective tissue disease (n = 339, 5.0%), miscellaneous (n = 277, 4.1%), crystal arthritis (n = 269, 4.0%), psoriatic arthritis (n = 242, 3.6%), and pain syndromes (n = 143, 2.1%). The specific diseases which were categorised under crystal arthritis, other connective tissue disease, and miscellaneous are shown in **Supplementary Table 2**.

#### Distribution of article placement within issues

Inspection of the cumulative distribution function plots showed no association of article placement order with author gender, geographical region, or industry funding (Figure 1). However, differences in article placement order were observed for disease category (Figure 2 and Table 1). Articles about rheumatoid arthritis were more likely to be placed towards the front of issues. The placement of articles about ankylosing spondylitis, osteoarthritis and psoriatic arthritis conformed to a uniform distribution. Articles about systemic lupus erythematosus, other connective tissue diseases, crystal arthritis, systemic sclerosis, vasculitis, pediatric rheumatology and pain syndromes were more likely to be placed towards the back of issues.

Table 1. Difference in distribution	on of standard arti	icle placement indices	(SAPI) from a uniform districution fo	r each disease category
	N (%)	SAPI, mean (SD)	Difference in AUC betweef CDF ar	nd uniform distribution
			Mean (95% confidence interval) <sup>a</sup>	FDR-adjusted P
Ankylosing spondylitis	496 (7.3%)	0.51 (0.24)	+0.001 (-0.022, +0.014)	0.94
Crystal arthritis	269 (4.0%)	0.63 (0.28)	0.124 (0.141 0.110)	<0.001
Miscellaneous	277 (4.1%)	0.68 (0.29)	-0.182 (-0.205, -0.150) §	<0.001
Not disease-specific	422 (6.2%)	0.61 (0.30)	-0.134 (-0.141, -0.110) -0.182 (-0.205, -0.150) -0.092 (-0.103, -0.069) +0.002 (-0.014, +0.021)	<0.001
Osteoarthritis	773 (11.4%)	0.49 (0.24)	+0.002 (-0.014, +0.021)	0.88
Other connective tissue diseases	339 (5.0%)	0.62 (0.25)		<0.001
Pediatric rheumatology	443 (6.5%)	0.69 (0.28)	-0.110 (-0.127, -0.090) -0.190 (-0.230, -0.180) -0.183 (-0.260, -0.152) -0.012 (-0.045, 0.015) +0.144 (+0.141, +0.157) -0.073 (-0.087, -0.050)	<0.001
Pain syndromes	143 (2.1%)	0.69 (0.27)	-0.183 (-0.260, -0.152)	<0.001
Psoriatic arthritis	242 (3.6%)	0.53 (0.24)	-0.012 (-0.045, 0.015)	0.55
Rheumatoid arthritis	1946 (28.7%)	0.36 (0.28)	+0.144 (+0.141, +0.157)	<0.001
Systemic lupus erythematosus	642 (9.5%)	0.58 (0.21)	-0.073 (-0.087, -0.050)	<0.001
Systemic sclerosis	433 (6.4%)	0.64 (0.24)	-0.140 (-0.147, -0.122)	<0.001
Vasculitis	362 (5.3%)	0.65 (0.24)	-0.140 (-0.147, -0.122) -0.154 (-0.180, -0.122)	<0.001

AUC = area under the curve; CDF = cumulative density function; SAPI = standard articles placement index. <sup>a</sup>Positive differences indicate deviations from a uniform distribution above the uniform distribution function (i.e. article skewed towards the front of an issue), while negative differences indicate deviations from a uniform distribution below the uniform distribution function (i.e. article skewed towards the back of an issue).

#### Articles in the first and last three places of an issue

There were no significant differences in the proportion of articles in the first vs. last three places of an issue for author gender, geographical regions, or industry funding category (**Supplementary Table 3**). However, consistent with the cumulative distribution function analysis, differences for disease category were observed (**Figure 3 and Supplementary Table 3**). There was a significantly greater proportion of articles in the first three compared to the last three places of an issue for rheumatoid arthritis (35.6% vs. 8.7% P < 0.001) with an OR (95% CI) of 5.77 (4.80, 6.92). There was a similar proportion of articles in the first three and last three places of an issue for ankylosing spondylitis, osteoarthritis, or psoriatic arthritis. There was a significantly lower proportion of articles in the first three compared to the last three places of an issue for crystal arthritis (10.8% vs. 26.8%), other connective tissue diseases (6.8% vs., 16.5%), pediatric rheumatology (8.4% vs. 38.8%), pain syndromes (8.4% vs. 37.1%), systemic lupus erythematosus (4.7% vs. 9.7%), systemic sclerosis (4.4% vs. 18.2%) and vasculitis (6.4% vs. 18.0%) (all P < 0.001).

#### Journals with and without content grouped by disease category

Arthritis & Rheumatology, Seminars in Arthritis and Rheumatism, Arthritis Care & Research and The Journal of Rheumatology grouped issue content by disease category with disease-specific tables of contents sections, while Annals of the Rheumatic Diseases, Rheumatology, and Joint Bone Spine did not group issue content by disease category (Supplementary Table 1). Journals with content grouped by disease showed an association between article placement order and disease category, whereas this was less evident for journals without content grouped by disease (Figure 4). Comparisons between journals with and without content grouped by disease category demonstrated a significant difference in the SAPI

distributions for every disease category, with articles on rheumatoid arthritis placed towards the front of issues, and articles on crystal arthritis, pain syndromes, pediatric rheumatology, systemic sclerosis and vasculitis placed towards the end of issues, in journals with content grouped by disease category (**Supplementary Table 4**).

#### The impact of article placement order on Altmetric scores and downloads

The impact of article placement order was evident in the meta-analysis results, which showed a higher Altmetric score (adjusted for journal) for articles published in the first three places of an issue compared with the last three, (mean difference in Altmetric score of 5.11, 95% CI 1.50, 8.71, Z = 2.78, P = 0.005) (**Figure 5**). The difference in Altmetric scores varied across different disease categories ( $I^2$  76%; P < 0.001), with the largest difference between positioning in the first three places and positioning in the last three places being observed for articles about rheumatoid arthritis and psoriatic arthritis.

Similarly, meta-analysis showed that articles published in the first three places of an issue had a higher download rate compared to articles in the last three places of an issue (pooled rate difference (95% CI) 442.1 (293.0, 591.2) downloads/article year, Z = 5.81, P < 0.001) (**Figure 5**). The difference in download rate between the first and last three articles was similar across different disease categories ( $I^2$  24%; P = 0.21).

#### **DISCUSSION**

In this analysis of serial rheumatology journals, no relationship between article placement order and author gender, geographical region or industry sponsorship was observed.

However, differences for disease category were apparent, with more frequent positioning of

articles about rheumatoid arthritis towards the front of journal issues, and articles about crystal arthritis, other connective tissue diseases, pediatric rheumatology, pain syndromes, systemic lupus erythematosus, systemic sclerosis and vasculitis towards the back of issues. Analyses of Altmetric scores and download rates suggested that article placement order influences research prominence, with earlier placed articles receiving more attention.

Medical journals are central to evidence-based practice and represent a key source of new knowledge for medical professionals.[18, 19] Unbiased publication practices are important in allowing a variety of perspectives and emphases to expand the scope of research and clinical practice. Although bias has been previously reported in academic journals based on authorship ordering of genders,[9, 10] representation of geographical regions,[9, 11] and acceptance and time to publication based on industry sponsorship,[12] our analysis showed that these factors were not associated with article placement order within serial rheumatology journals.

Articles about rheumatoid arthritis were preferentially placed towards the front of rheumatology journals, while other conditions, particularly pain syndromes, crystal arthritis, pediatric syndromes, and connective tissue diseases, were ordered towards the back.

Rheumatoid arthritis was the disease category with the greatest number of articles, therefore giving it the greatest opportunity to be listed first, but our analyses accounted for the variation in article numbers between disease categories. Although rheumatoid arthritis is a very important rheumatic disease,[20] general rheumatology practice involves the diagnosis and treatment of a wide range of diseases.[21, 22] General rheumatology journals should ideally reflect that diversity of clinical practice. A similar distribution of articles on each disease category would therefore be expected if there was no bias for disease category.

The reason for the observed differences in article placement for disease category is unclear. Disease privileging in other fields of medical research has been reported, with some prevalent diseases with high global impact being under-funded and under-researched.[13-15] Crystal arthritis, osteoarthritis and pain syndromes are common and have high global burden,[23-25] but may be viewed by rheumatologists and journal editors as less important or less severe.[26, 27] These perceptions of some rheumatic diseases have the potential to impact attitudes in clinical practice and contribute to lower quality of care.[27, 28] Rheumatic diseases such as vasculitis, pediatric rheumatic disease, and scleroderma are less common, but can lead to major morbidity and reduced quality of life. Improving the impact and accessibility of research published on 'lower priority' or less common rheumatic diseases may have an important impact on clinicians' understanding about and attitudes towards these conditions in clinical practice.

Differences in article placement order for disease category was particularly evident in journals with disease-specific tables of contents sections within issues, rather than journals that did not group issue content by disease category. It has been suggested that grouping article content by disease category may improve the reader experience.[29] However, such decisions have the potential to further reduce readers' exposure to diseases that are already under-studied or less well understood. Editorial decisions to remove grouping by disease category, or to cycle the order of disease category groups for each issue may be a simple solution to overcome bias for disease category reflected in article placement order.

In our analysis, articles appearing in the first three places of an issue had higher Altmetric scores and download rates compared to articles appearing in the last three places of an issue. This is consistent with prior studies which also demonstrate the impact of the primacy effect on research prominence.[6-8] Collectively, these findings indicate that articles placed at the front of journal issues receive greater prominence. The prominence and impact of research

published in journals has an important role in not only providing information to improve knowledge and treatment, but also in financing further research[30] and obtaining academic promotion.[31]

The current analysis has some limitations. Firstly, Altmetric and download data were not available from all journals included in the analysis, and it is unclear whether similar differences are present across all journals. Secondly, citation rates were not evaluated because of the short time period between article publication and data extraction which would not have reflected true citation rates, which increase over time. Finally, this analysis did not explore other factors that may have contributed to article placement order such as quality, impact, or originality of the study, or the presence of prolific or "star" authors.[32]

In conclusion, author gender, geographical region, or funding source do not influence article placement order in serial rheumatology journals. However, bias for certain disease categories is reflected in article placement order. Article placement order may have an impact on research prominence, including Altmetric scores and download rate. Editorial choices about the serial position of articles within journals can influence prioritisation of certain diseases.

#### Acknowledgements

None.

#### **Competing interests**

ND has received consulting fees, speaker fees or grants from AstraZeneca, Horizon, Amgen, Dyve Bio, Hengrui, Abbvie, Pfizer, and Janssen, outside the submitted work. ND and SS work primarily in the field of gout research (a condition that was analysed in this research project). GG and AG declare no competing interests.

#### **Funding**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

#### **Author contributions**

SS contributed towards acquisition, analysis and interpretation of the data. GG contributed towards design of the study and analysis and interpretation of the data. AG contributed towards design of the study and interpretation of the data. ND contributed towards design of the study, and acquisition and interpretation of the data. All authors were involved in drafting of the work or revising it critically for important intellectual content. All authors approved the final version to be published and agree to be accountable for all aspects of the work.

#### **Data statement**

All extracted data used in the analyses are available upon reasonable request from the corresponding author.



#### REFERENCES

- [1] Chen E, Simonovits G, Krosnick JA, Pasek J. The impact of candidate name order on election outcomes in North Dakota. *Elect Stud* 2014;35:115–22.
- [2] Becker SL. Why an order effect? *Public Opin Q* 1954;18:271–8.
- [3] Mantonakis A, Rodero P, Lesschaeve I, Hastie R. Order in choice: effects of serial position on preferences. *Psychol Sci* 2009;20:1309–12.
- [4] Eysenbach G, Köhler C. How do consumers search for and appraise health information on the world wide web? Qualitative study using focus groups, usability tests, and in-depth interviews. *BMJ* 2002;324:573–7.
- [5] Haque A-u, Ginsparg P. Positional effects on citation and readership in arXiv. *J Assoc Inf Sci Technol* 2009;60:2203–18.
- [6] Novarese M, Wilson CM. Being in the right place: a natural field experiment on list position and consumer choice. MPRA Paper 48074, University Library of Munich, Germany; 2013.
- [7] Jonah B. Does presentation order impact choice after delay? *Top Cogn Sci* 2016;8:670–84.
- [8] Feenberg D GI, Gaule P, Gruber J. It's Good to be First: Order Bias in Reading and Citing NBER Working Papers. *Rev Econ Stat* 2015;99:32–9.
- [9] Filardo G, da Graca B, Sass DM, Pollock BD, Smith EB, Martinez MA-M. Trends and comparison of female first authorship in high impact medical journals: observational study (1994-2014). *BMJ* 2016;352:i847.
- [10] West JD, Jacquet J, King MM, Correll SJ, Bergstrom CT. The role of gender in scholarly authorship. *PLoS One* 2013;8:e66212.

- [11] Edwards HA, Schroeder J, Dugdale HL. Gender differences in authorships are not associated with publication bias in an evolutionary journal. *PLoS One* 2018;13:e0201725.
- [12] Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. *BMJ* 2003;326:1167–70.
- [13] Yegros A, Tijssen R, Abad-García M-F, Ràfols I. Drug research priorities at odds with global disease toll [Blog]. Nature Index 2018. Accessed on 6/8/2019 from: https://www.natureindex.com/news-blog/drug-research-priorities-at-odds-with-global-disease-toll
- [14] Lobner K, Lanzkron S, MHS, Haywood C. NIH and National Foundation expenditures for sickle cell disease and cystic fibrosis are associated with Pubmed publications and FDA approvals. *Blood* 2013;122:1739.
- [15] Catalá-López F, García-Altés A, Álvarez-Martín E, Gènova-Maleras R, Morant-Ginestar C. Does the development of new medicinal products in the European Union address global and regional health concerns? *Popul Health Metr* 2010;8:34-43.
- [16] Altman DG, Bland JM. How to obtain the P value from a confidence interval. *BMJ* 2011;343:d2304.
- [17] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* 1995;57:289–300.
- [18] Christine Laine M, MPH, David S. Weinberg M, MSc. How can physicians keep upto-date? *Annu Rev Med* 1999;50:99–110.
- [19] Sackett DL, Rosenberg WM. The need for evidence-based medicine. *JRSM* 1995;88:620–4.
- [20] Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73:1316–22.

- [21] Ng X, Low AHL, Chew L-C, et al. Disease patterns of rheumatology outpatients seen in a tertiary hospital serving a multi-ethnic, urban Asian population in Singapore. *Int J Rheum Dis* 2013;16:273–8.
- [22] Miedema HS, van der Linden SM, Rasker JJ, Valkenburg HA. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. *Rheumatol* 1998;37:555–61.
- [23] Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73:1470–6.
- [24] Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study.

  \*\*Ann Rheum Dis 2014;73:1323-30.\*\*
- [25] Hoy D, March L, Brooks P, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73:968–74.
- [26] Birrell F, Arden NK, Conaghan PG, Cooper C, Dieppe P, Doherty M. Is it time for more rheumatologists to embrace osteoarthritis? *Rheumatol* 2005;44:829-30.
- [27] Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269–70.
- [28] Chua JR, Jamal S, Riad M, et al. Disease burden in osteoarthritis is similar to that of rheumatoid arthritis at initial rheumatology visit and significantly greater six months later.

  \*Arthritis Rheumatol 2019; doi: 10.1002/art.40869
- [29] Smolen JS. Greetings from the editor 2019. Ann Rheum Dis 2019;78:1–2.
- [30] Cabezas-Clavijo A, Robinson-García N, Escabias M, Jiménez-Contreras E. Reviewers' ratings and bibliometric indicators: hand in hand when assessing over research proposals? *PLoS One* 2013;8:e68258.

- [31] Holden G, Rosenberg G, Barker K. Bibliometrics: a potential decision making aid in hiring, reappointment, tenure and promotion decisions. *Soc Work Health Care* 2005;41:67–92.
- [32] Tomkins A, Zhang M, Heavlin WD. Reviewer bias in single- versus double-blind peer review. *Proc Natl Acad Sci U S A* 2017;114:12708-1



#### Figure legends


**Figure 1.** Cumulative distribution function plots of standardised article placement indices (SAPI) for first author gender (**A.**), senior author gender (**B.**), industry funding (**C.**), and first author's geographic region of affiliated institution (**D.**). Left skewed distributions suggest prioritisation towards the front of journal issues.


**Figure 2.** Cumulative distribution function plots of standardised article placement indices (SAPI) for each disease category. Left skewed distributions suggest prioritisation towards the front of journal issues.

**Figure 3.** Percentage of articles (per disease category) published in first three and last three places of an issue (*P*-values indicate difference between proportions of articles in first and last three places of an issue).

**Figure 4.** Cumulative distribution function plots of standardised article placement indices (SAPI) for each disease category for journals with (**A.**) and without (**B.**) contents grouped by disease. Left skewed distributions suggest prioritization towards the front of journal issues.

**Figure 5.** Forest plots showing the mean differences for each disease category for Altmetric scores (**A.**) and download rates (**B.**) between articles published in the first vs. last three places of an issue. Positive differences indicate a higher Altmetric score/download rate for articles published in one of the first three places of an issue. Differences in Altmetric scores are adjusted for journal. Download data was available from one journal. CTD: connective tissue disease.





Orystal arthritis Ankylosing spondylitis Miscellaneous


Not disease-specific Osteoarthritis Pediatric rheumatology

Pain syndromes Psoriatic arthritis Rheumatoid arthrigis


Systemic lupus erythematosus Systemic sclerosis


Other connective tissue disease of Vasculitis


# A. Journals with issue content grouped by disease




# B. Journals without issue content grouped by disease









For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### 

## A. Differences in Altmetric scores between articles in first and last three places of an issue

	First thr	First three Last three Score						が Mean difference, random effects
	Mean score	N	Mean score	N	Weight	difference	95% CI	analysis, 95% CI
Ankylosing spondylitis	14.19	32	6.10	31	7.44%	8.09	(-0.70, 16.88)	<u> </u>
Crystal arthritis	9.10	21	25.23	39	2.90%	-16.14	(-34.85, 2.58)	<del></del>
Miscellaneous	10.95	20	4.18	50	9.93%	6.77	(0.99, 12.55)	
Not disease-specific	28.47	36	7.73	66	2.40%	20.74	(-0.33, 41.82)	June
Osteoarthritis	18.47	47	20.26	47	4.20%	-1.79	(-16.35, 12.77)	<del>-</del> 2
Other CTDs	6.421	19	3.57	47	11.91%	2.85	(-0.58, 6.27)	2020.
Pediatric rheumatology	7.14	29	5.57	86	11.63%	1.57	(-2.21, 5.35)	— — — — — — — — — — — — — — — — — — —
Pain syndromes	48.36	11	26.10	29	0.61%	22.26	(-22.78, 67.30)	<del> </del>
Psoriatic arthritis	13.00	17	3.00	17	8.38%	13.06	(5.46, 20.65)	- <b>■</b> -
Rheumatoid arthritis	24.16	434	4.03	156	9.01%	20.13	(13.29, 26.97)	-■- 등
Systemic lupus erythematosus	12.59	27	7.69	58	7.69%	4.90	(-3.55, 13.36)	<del>  •                                     </del>
Systemic sclerosis	3.88	17	2.81	69	12.50%	1.07	(-1.49, 3.63)	<b>₽</b> 0.
Vasculitis	2.68	22	4.41	37	11.42%	-1.72	(-5.77, 2.33)	ownloaded from
Total		732		732	100.0	5.11	(1.50, 8.71)	
	υ,		25.3; Chi <sup>2</sup> = 49.8 : Z = 2.78; P = 0.	•	9% (P < 0.00	01)		-40 -20 0 20 40 50  Last three First three

B. Differences in download rates between articles in first and last three places of an issue

	First thr	ee	Last thro	ee		Rate		ਮੁੱਤ Mean difference, random
	Mean score	N	Mean score	N	Weight	difference	95% CI	effects analysis, 95% CI
Ankylosing spondylitis	842.8	17	344.9	10	10.9%	497.9	(115.6, 880.3)	20
Crystal arthritis	726.3	9	198.1	5	8.88%	528.3	(89.2, 967.3)	2024
Miscellaneous	1073.5	7	385.3	12	5.18%	688.1	(78.7, 1297.6)	<del></del>
Not disease-specific	1430.0	15	336.0	15	1.95%	1093.9	(54.7, 2133.1)	
Osteoarthritis	465.5	13	457.2	22	12.04%	8.2	(-347.9, 364.4)	guest.
Other CTDs	785.3	5	389.1	14	8.40%	396.2	(-58.7, 851.1)	<del>  ■</del>
Pediatric rheumatology	758.2	6	626.0	4	3.07%	132.2	(-683.7, 948.1)	
Pain syndromes	1110.5	3	346.4	1	0.00%	Excluded		Prote
Psoriatic arthritis	1408.0	14	491.8	3	1.20%	916.2	(-426.3, 2258.7)	
Rheumatoid arthritis	952.2	76	358.8	54	24.23%	593.4	(409.2, 777.6)	cted by
Systemic lupus erythematosus	880.0	11	538.7	12	10.36%	341.3	(-54.6, 737.2)	<del></del>
Systemic sclerosis	480.6	5	286.8	25	9.19%	193.9	(-235.4, 623.1)	
Vasculitis	961.3	3	142.0	6	4.59%	819.3	(165.95, 1472.7)	<del></del>
Total		183		184	100.0	442.1	(293.0, 591.2)	→ CO OPYTIGHT 1::1

Heterogeneity: Tau<sup>2</sup> = 15400; Chi<sup>2</sup> = 14.4; I<sup>2</sup> = 23.7% (P = 0.211)

For president from Expression (P = 0.211)

Last three

First three

6/bmjopen-2019-034550 on 17 June 202<mark>0</mark>.

#### SUPPLEMENTARY MATERIAL

Supplementary Tables

Supplementary Table 1. Journal characteristics

	Publisher	Country of publication	2016 Impact Factor	Relevant affiliated society	Issues per	Sontents Fourtents Fourped by	Total number of articles included, n	Number of included articles per issue, mean (SD)
Annals of the Rheumatic Diseases	BMJ Publishing Group Ltd	United Kingdom	12.811	European League Against Rheumatism	12	<b>§</b> 0 <b>⇒</b>	1374	13.2 (9.4)
Arthritis & Rheumatology	John Wiley & Sons	United States	6.918	American College of Rheumatology	12	ges Es	1367	12.5 (7.6)
Rheumatology	Oxford University Press	United Kingdom	4.818	British Society for Rheumatology	12	h <b>₹</b> 0://	1158	10.2 (5.7)
Seminars in Arthritis and Rheumatism	Elsevier	United States	4.498	None	6	Amjo ves	403	7.3 (4.1)
Joint Bone Spine	Elsevier	United States	3.329	French Society of Rheumatology	6	n n n n n n n n n n n n n n n n n n n	239	4.6 (2.6)
Arthritis Care & Research	John Wiley & Sons	United States	3.319	American College of Rheumatology, Association of Rheumatology Health Professionals	12	. Yes j. co	1098	9.6 (5.4)
The Journal of Rheumatology	Journal of Rheumatology Publishing Company Limited	Canada	3.150	Canadian Rheumatology Association	12	in established to the second	1148	10.3 (6.1)

Supplementary Table 2. Number of articles within each disease category for crystal arthritis, miscellaneous and other connective tissue diseases

Cystal arthritis (n = 269)	other connective tissue diseases	Frequency	Percent
Miscellameous Disease (n = 277 articles)	Crystal arthritis (n = 269)	- •	
Miscellaneous Disease (n = 277 articles)           Regional musculoskeletal syndromes         48         17,3           Osteoporosis         22         7,9           IgG4-related disease         20         7,2           FMF         20         7,2           Polymyalgia rheumatica         19         6,9           CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Saccidosis         7         2.5           Chikunganya Virus         7         2.5           SAPHO syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Danlos Syndrome         4         1.4           Lyme disease         4         1.4           Alkaptonuria         4         1.4           Hemophagocytic syndromes         2         0.7           Uvertis         2         0.7           Undifferentiated arthritis         2         0.7           Uvertis         2         0.7           Uretis	Gout	260	96.7
Regional musculoskeletal syndromes         48         17.3           Osteoprosis         22         7.9           IgG4-related disease         20         7.2           FMF         20         7.2           Polymyalgia rheumatica         19         6.9           CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Succidosis         7         2.5           Chikungunya Virus         7         2.5           SAPHO syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Danlos Syndrome         4         1.4           Alkaptomuria         4         1.4           Hemophagocytic syndromes         3         1.1           Vertebral fractures         2         0.7           Urbeitia         2         0.7           Urbeitia         2         0.7           Urbeitia frecurs         2         0.7           Urbeitorius fever syndrome         2         0.7	Calcium crystal diseases	9	3.3
Osteoporosis         22         7.9           IgG4-related disease         20         7.2           FMF         20         7.2           Polymyalgia rheumatica         19         6.9           CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Sarcoidosis         7         2.5           Chikungunya Virus         7         2.5           SAPHO syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Danlos Syndrome         4         1.4           Lyme disease         4         1.4           Alkaptomria         4         1.4           Hemophagocytic syndromes         3         1.1           Vertebral fractures         2         0.7           Uveitis         2         0.7           Urdifferentiated arthritis         2         0.7           Urberalolis (ever syndrome         2         0.7           Erdheim-Chester disease         2         0.7	Miscellaneous Disease (n = 277 articles)		
IgG4-related disease         20         7.2           FMF         20         7.2           Polymyalgia rheumatica         19         6.9           CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Sarcoidosis         7         2.5           Chikungunya Virus         7         2.5           SAPHO syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Danlos Syndrome         4         1.4           Lyme disease         4         1.4           Alkaptonuria         4         1.4           Hemophagocytic syndromes         3         1.1           Vertebral fractures         2         0.7           Uveitis         2         0.7           Uveitis         2         0.7           Uveitis         2         0.7           Uveitis         2         0.7           Uveitis exercites         2         0.7           Erfheim-Chester disease	Regional musculoskeletal syndromes	48	17.3
FMF         20         7.2           Polymyalgia rheumatica         19         69           CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Saccidosis         7         2.5           Chikungunya Virus         7         2.5           SAPHO Syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Danlos Syndrome         4         1.4           Alkaptomuria         4         1.4           Hemophagocytic syndromes         3         1.1           Vertebral fractures         2         0.7           Uvetis         2         0.7           Uvetis         2         0.7           Urderidiferentiated arthritis         2         0.7           Periodic fever syndrome         2         0.7           Erdheim-Chester disease         2         0.7           Dupuytren's disease         2         0.7           Verlogene syndrome         1         0.4           <	Osteoporosis	22	7.9
Polymyalgia rheumatica         19         6.9           CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Sarcoidosis         7         2.5           Chikungunya Virus         7         2.5           SAPHO syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Daniot Syndrome         4         1.4           Lyme disease         4         1.4           Alkaptonuria         4         1.4           Hemophagocytic syndromes         3         1.1           Vertebral fractures         2         0.7           Uveitis         2         0.7           Erderentiated arthritis         2         0.	IgG4-related disease	20	7.2
CAPS         16         5.8           Still's disease         10         3.6           Septic arthritis         8         2.9           Fibrosis         8         2.9           Sarcoidosis         7         2.5           Chikungunya Virus         7         2.5           SAPHO syndrome         6         2.2           TRAPS         5         1.8           Polychondritis         5         1.8           Ehlers-Danlos Syndrome         4         1.4           Llyme disease         3         1.1           Vertebral fractures         2         0.7           Uvetitis         2         0.7           Uvetitis         2         0.7           Uberculosis         2         0.7           Priberculosis         2         0.7           Priberculosi fever syndrome         2         0.7           Erdheim-Chester disease         2         0.7           Prilamein-Chester disease </td <td>FMF</td> <td>20</td> <td>7.2</td>	FMF	20	7.2
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Polymyalgia rheumatica	19	6.9
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	CAPS	16	5.8
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Still's disease	10	3.6
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Septic arthritis	8	2.9
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Fibrosis	8	2.9
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Sarcoidosis	7	2.5
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Chikungunya Virus	7	2.5
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	SAPHO syndrome	6	2.2
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	TRAPS	5	1.8
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Polychondritis	5	1.8
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Ehlers-Danlos Syndrome	4	1.4
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Lyme disease	4	1.4
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Alkaptonuria	4	1.4
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Hemophagocytic syndromes	3	1.1
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Vertebral fractures	2	0.7
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Uveitis	2	0.7
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Undifferentiated arthritis	2	0.7
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Tuberculosis	2	0.7
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Periodic fever syndrome	2	0.7
Dupuytren's disease ACPA-negative undifferentiated arthritis 1 0.4 Yellow fever 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Primented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4 Preedict fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Löfgren syndrome	2	0.7
ACPA-negative undifferentiated arthritis  ACPA-negative undifferentiated arthritis  Yellow fever  1 0.4  Whipple disease 1 0.4  Vertebral endplate lesions 1 0.4  Tumoral calcinosis 1 0.4  Tenosynovial giant cell tumor 1 0.4  Systemic autoinflammatory disease (SAID) 1 0.4  Schnitzler's syndrome 1 0.4  Ribbing disease 1 0.4  Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Preeclampsia 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Erdheim-Chester disease	2	0.7
Yellow fever 1 0.4 Whipple disease 1 0.4 Whipple disease 1 0.4 Vertebral endplate lesions 1 0.4 Tumoral calcinosis 1 0.4 Tenosynovial giant cell tumor 1 0.4 Systemic autoinflammatory disease (SAID) 1 0.4 Schnitzler's syndrome 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Primary angiitis of the CNS 1 0.4 Priecclampsia 1 0.4 Precclampsia 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Dupuytren's disease	2	0.7
Whipple disease Vertebral endplate lesions 1 0.4  Tumoral calcinosis 1 0.4  Tenosynovial giant cell tumor 1 0.4  Systemic autoinflammatory disease (SAID) 1 0.4  Schnitzler's syndrome 1 0.4  Ribbing disease 1 0.4  Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Preiodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	ACPA-negative undifferentiated arthritis	1	0.4
Vertebral endplate lesions  1 0.4  Tumoral calcinosis 1 0.4  Tenosynovial giant cell tumor 1 0.4  Systemic autoinflammatory disease (SAID) 1 0.4  Schnitzler's syndrome 1 0.4  Ribbing disease 1 0.4  Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Pyogenic arthritis 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Yellow fever	1	0.4
Tumoral calcinosis  1 0.4  Tenosynovial giant cell tumor 1 0.4  Systemic autoinflammatory disease (SAID) 1 0.4  Schnitzler's syndrome 1 0.4  Ribbing disease 1 0.4  Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Pyogenic arthritis 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Whipple disease	1	0.4
Tenosynovial giant cell tumor  Systemic autoinflammatory disease (SAID)  1 0.4  Schnitzler's syndrome 1 0.4  Ribbing disease 1 0.4  Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Pyogenic arthritis 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Vertebral endplate lesions	1	0.4
Systemic autoinflammatory disease (SAID)  Schnitzler's syndrome  1 0.4  Ribbing disease 1 0.4  Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Pyogenic arthritis 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Tumoral calcinosis	1	0.4
Schnitzler's syndrome 1 0.4 Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Pyogenic arthritis 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Pigmented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Tenosynovial giant cell tumor	1	0.4
Ribbing disease 1 0.4 Receptor-associated periodic syndrome 1 0.4 Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4 Pyogenic arthritis 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Pigmented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Systemic autoinflammatory disease (SAID)	1	0.4
Receptor-associated periodic syndrome 1 0.4  Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Pyogenic arthritis 1 0.4  Primary angiitis of the CNS 1 0.4  Precelampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Schnitzler's syndrome	1	0.4
Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome 1 0.4  Pyogenic arthritis 1 0.4  Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Ribbing disease	1	0.4
Pyogenic arthritis 1 0.4 Primary angiitis of the CNS 1 0.4 Preeclampsia 1 0.4 Pigmented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Receptor-associated periodic syndrome	1	0.4
Primary angiitis of the CNS 1 0.4  Preeclampsia 1 0.4  Pigmented villonodular synovitis 1 0.4  Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome	1	0.4
Preeclampsia 1 0.4 Pigmented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Pyogenic arthritis	1	0.4
Pigmented villonodular synovitis 1 0.4 Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Primary angiitis of the CNS	1	0.4
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) 1 0.4	Preeclampsia	1	0.4
	Pigmented villonodular synovitis	1	0.4
syndrome		1	0.4
	syndrome		

Paraneoplastic rheumatic syndrome	1	0.4
Palindromic rheumatism	1	0.4
Paget's disease	1	0.4
Osteonecrosis	1	0.4
Osteomyelitis	1	0.4
NOD2-associated autoinflammatory diseases	1	0.4
Muckle-wells syndrome	1	0.4
Mikulicz's disease	1	0.4
Mevalonate kinase deficiency	1	0.4
Medial meniscal tears	1	0.4
Macrophage activation syndrome	1	0.4
Leri's pleonosteosis	1	0.4
Kikuchi-Fujimoto disease	1	0.4
Joint hypermobility syndrome	1	0.4
Immune reconstitution inflammatory syndrome	1	0.4
Hereditary recurrent fever syndromes	1	0.4
Hereditary haemochromatosis	1	0.4
Haploinsufficiency of A20	1	0.4
Glomerulonephritis	1	0.4
Gaucher disease	1	0.4
Femoral fractures	1	0.4
Fabry disease	1	0.4
Ebola virus	1	0.4
Discitis	1	0.4
Chronic graft-versus-host disease	1	0.4
Blau syndrome	1	0.4
Biphosphate trochanteric fracture	1	0.4
Amyloidosis	1	0.4
Hereditary haemochromatosis Haploinsufficiency of A20 Glomerulonephritis Gaucher disease Femoral fractures Fabry disease Ebola virus Discitis Chronic graft-versus-host disease Blau syndrome Biphosphate trochanteric fracture Amyloidosis Aicardi-Goutières syndrome	1	0.4
Other connective tissue disease (n = 339 articles)		
Sjogren's syndrome	174	51.3
Inflammatory myositis	115	33.9
Antiphospholipid syndrome	41	12.1
Mixed connective tissue disease	7	2.1
CTD-associated interstitial lung disease	1	0.3
Undifferentiated connective tissue disease	1	0.3

BMJ Open

BMJ Open

Supplementary Table 3. Number of articles appearing in at least one article in first and last three articles of an issue for author gender, geographical region of affiliated institution, industry funding category, and disease category funding category, and disease category

funding category, and disease category	TD - 4 - 1 42 - 1	ee	Last thr	ee	Odds ratio -		$P^{\mathrm{b}}$	
	Total articles	N	% of total	N	% of total	(OR) <sup>a</sup>	95% CI for OR	$P^{\omega}$
First author gender								
Female	3517	537	15.3%	586	16.7%	0.70	o.79, 1.02	0.17
Male	3250	557	17.1%	509	15.7%	1.11	0.98, 1.27	0.17
Last author gender							20	
Female	2359	393	16.7%	355	15.0%	1 13	0.97 1.32	0.17
Male	4412	705	16.0%	737	16.7%	0.95	0.85, 1.01	0.37
Geographical region of affiliated institution							v n	
(first author)							5	
North America	2177	362	16.6%	352	16.2%	1.03	0.88, 1.21	0.68
Europe	3486	573	16.4%	556	16.0%	1.04	0.91, 1.18	0.68
Other	1124	163	14.5%	190	16.9%	0.83	<b>⇒</b> 0.66, 1.05	0.35
Industry funding								
Industry-funded and initiated	640	104	16.3%	109	17.0%	0.95	0.70, 1.27	0.71
Industry-funded and investigator-initiated	596	87	14.6%	111	18.6%	0.75	0.55, 1.01	0.09
Not industry-funded	5551	907	16.3%	878	15.8%	1.04	0.94, 1.15	0.09
Disease category			- L					
Ankylosing spondylitis	496	47	9.5%	40	8.1%		5· 0.77, 1.86	0.51
Crystal arthritis <sup>c</sup>	269	29	10.8%	72	26.8%	0.33	0.21, 0.53	< 0.001
Miscellaneous	277	28	10.1%	103	37.2%	0.19	0.12, 0.30	< 0.001
Not disease-specific	422	52	12.3%	121	28.7%	0.35	0.24, 0.50	< 0.001
Osteoarthritis	773	81	10.5%	82	10.6%	0.99	0.71, 1.37	0.934
Other connective tissue diseases	339	23	6.8%	56	16.5%	0.37	0.22, 0.61	< 0.001
Pediatric rheumatology	443	37	8.4%	172	38.8%	0.14	0.10, 0.21	< 0.001
Pain syndromes	143	12	8.4%	53	37.1%	0.16	9 0.08, 0.31	< 0.001
Psoriatic arthritis <sup>c</sup>	242	26	10.7%	23	9.5%	1.15	0.63, 2.07	0.71
Rheumatoid arthritis	1946	692	35.6%	170	8.7%	5.77	4.80, 6.92	< 0.001
Systemic lupus erythematosus	642	30	4.7%	62	9.7%	0.46	0.29, 0.72	0.001
Systemic sclerosis	433	18	4.4%	79	18.2%	0.19	ີ 0.11, 0.33	< 0.001
Vasculitis	362	23	6.4%	65	18.0%	0.31	o.19, 0.51	< 0.001

Vasculitis

362
23
6.4%
65
18.0%
0.31
20
0.19, 0.51

<a href="#page-16">O.19, 0.51</a>
<a href="#page-16">O.19, 0.19</a>
<a href="#page-16">O.

BMJ Open

BMJ Open

Supplementary Table 4. Difference in cumulative density function distribution of standard article placement indices (SAPI) between journals with and without contents grouped by disease for articles with related editorials and for each disease category. articles with related editorials and for each disease category

·	Journals with co	ontents not group	ed by disease	Journals with co	ntents grouped	by disease	Two-sample Kolmogorov-Smirnov Z test <sup>b</sup>		
	N (%)	SAPI <sup>a</sup>		N (%)	SAPI <sup>a</sup>		Effect size (D)	FDR-adjusted P	
		Mean	SD		Mean	SD	7 J		
Ankylosing spondylitis	228 (8.2%)	0.49	0.28	268 (6.7%)	0.52	0.19	0.20	< 0.001	
Crystal arthritis	137 (4.9%)	0.49	0.28	132 (3.3%)	0.78	0.20	0.50	< 0.001	
Miscellaneous	152 (5.5%)	0.62	0.30	125 (3.1%)	0.76	0.26	0.29	< 0.001	
Not disease-specific	178 (6.4%)	0.53	0.30	244 (6.1%)	0.66	0.29	0.22	< 0.001	
Osteoarthritis	231 (8.3%)	0.55	0.27	542 (13.5%)	0.47	0.22	0.20	< 0.001	
Other connective tissue diseases	167 (6.0%)	0.49	0.29	172 (4.3%)	0.70	0.17	0.36 oo	< 0.001	
Pediatric rheumatology	121 (4.4%)	0.48	0.26	322 (8.0%)	0.77	0.25	0.50	< 0.001	
Pain syndromes	41 (1.5%)	0.54	0.35	102 (2.5%)	0.75	0.21	0.36 중	0.001	
Psoriatic arthritis	109 (3.9%)	0.48	0.27	133 (3.3%)	0.56	0.20	0.22	0.005	
Rheumatoid arthritis	881 (31.8%)	0.51	0.29	1065 (26.5%)	0.23	0.20	0.49	< 0.001	
Systemic lupus erythematosus	193 (7.0%)	0.56	0.28	449 (11.2%)	0.58	0.17	0.19	< 0.001	
Systemic sclerosis	182 (6.6%)	0.60	0.30	251 (6.3%)	0.68	0.18	0.26	< 0.001	
Vasculitis	151 (5.4%)	0.51	0.28	211 (5.3%)	0.75	0.14	0.50	< 0.001	

<sup>\*</sup>Lower SAPI scores equate to articles ordered at the front of issues, while higher SAPI scores equate to articles ordered at the end of issues. \*Test of difference in distribution of SAPI between journals with and without contents grouped by disease sections. Bolded P-values indicated significant difference at < 0.05.

## **BMJ Open**

### Article Placement Order in Rheumatology Journals: A Content Analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-034550.R1
Article Type:	Original research
Date Submitted by the Author:	11-Dec-2019
Complete List of Authors:	Stewart, Sarah; The University of Auckland, Medicine Gamble, Greg; University of Auckland, Department of Medicine Grey, Andrew; University of Auckland Dalbeth, Nicola; University of Auckland,
 b>Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Evidence based practice
Keywords:	publication, bias, RHEUMATOLOGY

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

- 1 Article Placement Order in Rheumatology Journals: A Content Analysis
- 2 Sarah Stewart<sup>1</sup>, PhD
- 3 Greg Gamble<sup>1</sup>, MSc
- 4 Andrew Grey<sup>1</sup>, MD
- 5 Nicola Dalbeth<sup>1, 2</sup>, MD
- <sup>1</sup> School of Medicine, The University of Auckland, 85 Park Road, Grafton, Auckland 1062,
- 8 New Zealand
- <sup>2</sup> Corresponding author: School of Medicine, The University of Auckland, 85 Park Road,
- Grafton, Auckland 1062, New Zealand; n.dalbeth@auckland.ac.nz; +64 9 923 2568
- **12 Word count: 3208**

Abstract

- **Objectives.** To analyse variables associated with article placement order in serial
- 16 rheumatology journals.
- **Design.** A content analysis of original articles published in seven rheumatology journals from
- 18 2013-2018.
- **Methods**. The following data were extracted from 6,787 articles: order number of article in
- 20 issue, gender of first and last author, geographical region, industry funding, and disease
- 21 category. Cumulative density function plots were used to determine whether article
- 22 placement distribution was different from the expected distribution. Odds ratios for articles
- published in the first three places of an issue compared with the last three places were
- 24 calculated. Altmetric score and downloads were meta-analysed.
- **Results**. Article placement order did not associate with author gender, geographical region or
- funding source, but was associated with disease category. Articles about rheumatoid arthritis
- were more likely to be ordered at the front of issues (P<0.001). Articles about crystal
- arthritis, systemic lupus erythematosus, vasculitis, pain syndromes and pediatric rheumatic
- 29 diseases were more likely to be ordered at the end of issues (all P<0.001). Association of
- article placement order with disease category was observed only in journals with tables of
- 31 contents grouped by disease. Articles ordered in the first three places had higher Altmetric
- and download rates, than articles in the last three places.
- 33 Conclusions. Author gender, geographical region, or funding source do not influence article
- 34 placement order in serial rheumatology journals. However, bias for certain disease categories
- is reflected in article placement order. Editorial decisions about article placement order can
- influence the prominence of diseases.

**Keywords:** publication, bias, rheumatology



#### 40 Strengths and limitations of the study

- This is the first study to assess the relationship of article placement order in serial medical
   journals with author gender, geographical region of affiliated institution, industry funding
   or disease category.
- This content analysis included 6,787 articles from general rheumatology journals.
- This study also analysed the impact of article placement order on research prominence, including Altmetric scores and download rate.
- This analysis did not explore other factors that may have contributed to article placement order such as the originality of the study findings or the presence of "star" authors.

#### INTRODUCTION

The strong preference for items ordered first, and the important effect of list order on choice,
is well-recognised in consumer-based research.[1-3] In online searches for health
information, 97% of selected links were displayed in the first 10 results, while only 2% were
from the second or following pages.[4] For online academic repositories, earlier listed articles
were downloaded more frequently than later listed articles.[5] These primacy effects, which
increase when lists are longer,[6] may occur because earlier items, or those at the top of
tables of contents, are more visible and more likely to be seen and read.[5]
In academic publishing, the ordering of articles within a journal issue also affects the
prominence achieved by that research. Earlier listed articles received more citations over a 25
year period in a single journal.[7] The impact of ordering was also evident in an analysis of
emails sent to subscribers disseminating recent research papers listed in random order; with
the first paper having a 33% increase in views, 29% increase in downloads and 27% increase
in citations, regardless of research quality.[8]
A number of systemic biases have been reported in academic publishing. These include
preferential lead and senior authorship of men,[9, 10] higher acceptance rates for articles
from the US and Europe,[9, 11] preferential publication of industry-funded research,[12] and
disease privileging, wherein particular diseases receive preferential research funding and
publication.[13-15] It is unknown whether these systemic biases are reflected in article
placement order within medical journals. We analysed serial rheumatology journals for
relationships between article placement order and gender of the lead and senior authors,
geographical region of the affiliated institution, industry sponsorship, and disease category.

### **METHODS**

#### Patient and public involvement

- There was no patient or public involvement in the design, or conduct, or reporting, of this research.

#### Identification of journals and articles for inclusion

80 rheumatology journals. Journals were included if they produced regular issues, reported

This was a cross-sectional content analysis of original articles published in general

- original research and had 2016 Thomas Reuters Impact Factors of > 3.0. Journals were
- excluded if they published review articles only, were disease-specific (e.g. *Lupus*,
- 83 Osteoarthritis and Cartilage) or produced no issues. The following seven general
- rheumatology journals met the above criteria and were included: *Annals of the Rheumatic*
- 85 Diseases, Arthritis & Rheumatology, Arthritis Care & Research, Seminars in Arthritis and
- 86 Rheumatism, Rheumatology, Journal of Rheumatology, and Joint Bone Spine. Characteristics
- of the included journals are shown in **Supplementary Table 1**.
- All original articles published in the included journals in a five-year period from June 2013 to
- June 2018 were included in the analysis. To be included, articles could be full or concise
- 90 reports, and report on original basic science or clinical research, including systematic reviews
- and meta-analyses. Articles were excluded if they were from a disease-specific thematic issue
- or supplement, were narrative reviews, recommendations, guidelines, letters, or meeting
- 93 reports.

#### Data extraction

Data extraction was undertaken between June and December 2018. The following information was extracted for each included article: order number of article in the issue, gender of lead (first) author; gender of senior (final) author; geographical region of affiliated institution (for the first author); any industry sponsorship (industry-funded and initiated/industry-funded and investigator-initiated/not industry-funded); and, if available, the Altmetric score and number of downloads. The number of citations was not assessed because of the short time period between publication and data extraction. If author gender could not be determined by first name or by an internet search of the author's affiliated institution profile page, then the author's first name was entered into https://api.genderize.io/?name= which returns the gender and probability of certainty. Probabilities < 0.5 were labelled as "unknown" and not included in the gender-related analysis. If articles were authored by a single author, then this author's gender was entered under first author. Funding was assessed by review of funding statements, disclosures and author affiliations. Industry-funded studies were categorized as industry-funded and industry-initiated, or industry-funded and investigator-initiated, based on these statements. Studies with no evidence of industry funding were categorized as not industry-funded. Articles were coded according to the following 13 disease categories: ankylosing spondylitis and other spondyloarthropathy, crystal arthritis, osteoarthritis, miscellaneous rheumatic disease, pediatric rheumatology, pain syndromes, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis/scleroderma, other connective tissue disorders, vasculitis, and not disease-specific. The title of each article was used to determine the disease category. If there was uncertainty about the disease category from the title, then the abstract and/or full paper were reviewed. To ensure standardisation in data extraction, two authors (SS, ND) independently reviewed

eligible papers from ten randomly selected issues. A total of 208 articles were reviewed, with

kappas of 1.00 for author gender, geographic region and industry funding, while disease category had a kappa of 0.84 (86.1% agreement (95% confidence interval (CI) 81.0%, 90.5%)). All disease category disagreements were discussed to reach a consensus and a set of rules for categorising was established. The exercise was then repeated in which the two authors reviewed disease categories in a further five randomly selected issues totalling 85 articles, with a kappa of 0.99 (98.8% agreement (95% CI 94.3%, 99.9%)) for disease category. A single reviewer (SS) then independently extracted the data.

#### Data analysis

The primary analyses assessed the relationships between article placement order and: gender of first authors, gender of last authors, geographical region (North America vs. Europe vs. Other), industry funding categories (industry-funded and initiated vs. industry-funded and investigator-initiated vs. not industry-funded), and disease categories. In order to identify whether these factors were associated with article placement order within journal issues, each article within each issue was assigned a standard article placement index (SAPI), which was defined as the order of the article in the issue/total number of articles in the issue. For example, the first article in an issue of 21 articles was given an SAPI of 1/21 = 0.0476 and the last article 21/21 = 1. This metric allowed standardisation of article placement order within issues with the expectation that the number of articles within each issue would vary widely across different journals. For example, the SAPI could scale between article placement in a journal issue of five articles and one with 50 articles. Therefore, this metric addressed the large variation in the number of articles between different journal issues and overcame the potential issue of skewed average article placement order data resulting from issues with large numbers of articles. The SAPI as a placement metric enabled the

examination of article placement order without an assumption that the mean (or median) article placement order was different. Cumulative distribution functions (CDF) of SAPIs were analysed to determine the associations between article placement order and author gender, geographical region industry funding and disease category. A uniform distribution would be expected if there was no association with article placement order: deviations from the expected uniform distribution would support an association with article placement order. To test whether the distribution of SAPIs were different between author genders, geographical regions, and industry funding categories, two-sample Kolmogorov-Smirnov Z tests were conducted. Due to the sensitivity of this test [16], the effect sizes (D) were also computed with values ranging from 0 (no difference in distribution of SAPI between comparisons) to 1 (large difference in distribution of SAPI between comparisons) to provide further description of the deviations between the observed distributions. To determine whether the distribution of SAPIs for each disease category was different from a uniform distribution CDF (expected distribution if no bias reflected in article placement order), the area under the curve (AUC) of the observed CDF and uniform distribution CDF were each calculated using a trapezoidal method and the difference between these estimated for each of the 13 disease categories. Mean differences between the observed CDF and the uniform distribution CDF AUCs were computed from bootstrapped samples (500 replicates, sampled with replacement) and 95% confidence intervals estimated as the 2.5th and 97.5th percentile of the bootstrap distribution. P-values were calculated for each disease category from these confidence intervals using the method of Altman and Bland.[17] This analysis method allowed for an assumption-free comparison of the observed and expected distributions of SAPIs.[18] CDF-based comparisons are estimates and do not systematically increase or decrease with sample size. The estimated CDF, like an estimated mean, is unbiased at any sample size. The estimation of the CDF (like estimation of a mean) assumed only that each

variable examined provided some incremental information; that is, that collinearity was not close to perfect.[19] Unlike the comparison of a central tendency statistic (i.e. mean or median order placement), comparing these distributions allowed testing of any early and late article placement (bimodal) clustering (primacy and recency) as well as a uniform distribution of placement. CDF plots of SAPIs also provided a visually clear representation of article placement order and potential differences between groups.

A secondary analysis was undertaken to further explore article placement order, in which mid-P exact P-values were computed to compare the proportion of articles appearing in at least one of the first three places of an issue compared to at least one of the last three places of an issue for genders of first and last authors, geographical region, industry funding category, and each disease category. Odds ratios (OR) and their 95% CIs were also computed for articles in the first three places vs. last three places of an issue.

As some journals presented their content grouped by disease category, additional analyses were undertaken to determine whether article placement order of disease categories was different between journals which presented content grouped by disease category vs. journals without disease category content grouping. This was tested statistically using CDF plots of SAPI distributions, two-sample Kolmogorov Smirnov Z tests and effect sizes (D) as described above.

To further explore factors associated with article placement order, a supplementary *post hoc* analysis was undertaken to compare the median order of an article within an issue between genders, geographical regions, industry funding categories and disease categories using Mann-Whitney U or Kruskal Wallis tests, as appropriate.

Finally, to determine the impact of article placement order on Altmetric scores and article download rates (as available), meta-analyses were used to determine differences in the means for each variable between the first and last three articles in journal issues. Altmetric scores were provided by Arthritis & Rheumatology, Annals of the Rheumatic Diseases, Rheumatology and Arthritis Care & Research. Annals of the Rheumatic Diseases, Rheumatology and The Journal of Rheumatology had article download data available, but for the latter two journals, the data were available in only the 6 months prior to data extraction. Therefore, analyses of article downloads were undertaken for *Annals of the Rheumatic* Diseases only. For Altmetric scores, which generally do not change over time, mean scores were calculated by total Altmetric scores/total number of articles. For downloads, which are time dependent, rates were calculated by total number of downloads/total article-years from time of publication to time of data extraction. These analyses were undertaken within disease categories, adjusted by journal, as appropriate, and weighted using the inverse-variance method. Random effects models were used for all  $I^2$  values > 0%. All analyses were performed in SPSS (v25 IBM Corp), SAS v9.4 (SAS Institute Inc, Cary, NC) and openepi.com (v3.01). All tests were two-tailed and false discovery rate (FDR)adjusted P values [20] were computed for all analyses with an alpha level of < 0.05considered significant.

#### **RESULTS**

#### **Characteristics of included articles**

A total of 6,787 articles were included; 488 (7.2%) were randomised controlled trials, 438 (6.5%) were systematic literature reviews or meta-analyses, 4,466 (65.8%) were other clinical research studies, and 1,395 (20.6%) reported basic research. First authors were male in 3250

(47.9%) articles, female in 3517 (51.8%) articles and unknown in 20 (0.3%) articles. Last authors were male in 4412 (65.0%) articles, female in 2359 (34.8%) articles and unknown/not applicable in 16 (0.2%) articles. 596 (8.8%) articles were industry-funded and initiated, 640 (9.4%) were industry-funded and investigator-initiated, and 5551 (81.8%) were not industry-funded. The geographical region was North America in 2177 (32.1%) articles, Europe in 3486 (51.4%) articles, and Other in 1124 (16.6%) articles. Disease categories were rheumatoid arthritis (n = 1946, 28.7%), osteoarthritis (n = 773, 11.4%), systemic lupus erythematosus (n = 642, 9.5%), ankylosing spondylitis (n = 496, 7.3%), pediatric rheumatology (n = 443, 6.5%), systemic sclerosis (n = 433, 6.4%), not disease-specific (n = 422, 6.2%), vasculitis (n = 362, 5.3%), other connective tissue disease (n = 339, 5.0%), miscellaneous (n = 277, 4.1%), crystal arthritis (n = 269, 4.0%), psoriatic arthritis (n = 242, 3.6%), and pain syndromes (n = 143, 2.1%). The specific diseases which were categorised under crystal arthritis, other connective tissue disease, and miscellaneous are shown in **Supplementary Table 2**.

#### Distribution of article placement within issues

Inspection of the cumulative distribution function plots showed no association of article placement order with author gender, geographical region, or industry funding (**Figure 1**). However, differences in article placement order were observed for disease category (**Figure 2** and **Table 1**). Articles about rheumatoid arthritis were more likely to be placed towards the front of issues. The placement of articles about ankylosing spondylitis, osteoarthritis and psoriatic arthritis conformed to a uniform distribution. Articles about systemic lupus erythematosus, other connective tissue diseases, crystal arthritis, systemic sclerosis, vasculitis, pediatric rheumatology and pain syndromes were more likely to be placed towards

the back of issues. Analysis of the association between article placement order and research type demonstrated that articles reporting on randomised controlled trials, systematic literature reviews or meta-analyses, and other clinical research were more likely to be placed towards the front of issues compared to basic science research articles, with a significant difference in CDFs (all P < 0.05) (Supplementary Figure 1).



Table 1. Difference in distribution of standard article placement indices (SAPI) from a uniform distribution of SAPI, mean (SD)

N (%)

SAPI, mean (SD)

Macro (052/ confidence in 4

Table 1. Difference in distribution of standard article placement indices (SAPI) from a uniform distribution for each disease category									
	N (%)	SAPI, mean (SD)	Difference in AUC betweet CDF an	d uniform distribution					
			Mean (95% confidence interval) <sup>a</sup>	FDR-adjusted P					
Ankylosing spondylitis	496 (7.3%)	0.51 (0.24)	+0.001 (-0.022, +0.014)	0.94					
Crystal arthritis	269 (4.0%)	0.63 (0.28)	0.124 (0.141 0.110)	<0.001					
Miscellaneous	277 (4.1%)	0.68 (0.29)	-0.182 (-0.205, -0.150) §	<0.001					
Not disease-specific	422 (6.2%)	0.61 (0.30)	-0.092 (-0.103, -0.069)	<0.001					
Osteoarthritis	773 (11.4%)	0.49 (0.24)	+0.002 (-0.014, +0.021)	0.88					
Other connective tissue diseases	339 (5.0%)	0.62 (0.25)	-0.110 (-0.127, -0.090)	<0.001					
Pediatric rheumatology	443 (6.5%)	0.69 (0.28)	-0.134 (-0.141, -0.110) -0.182 (-0.205, -0.150) -0.092 (-0.103, -0.069) +0.002 (-0.014, +0.021) -0.110 (-0.127, -0.090) -0.190 (-0.230, -0.180) -0.183 (-0.260, -0.152) -0.012 (-0.045, 0.015) +0.144 (+0.141, +0.157) -0.073 (-0.087, -0.050)	<0.001					
Pain syndromes	143 (2.1%)	0.69 (0.27)	-0.183 (-0.260, -0.152) <del>=</del>	<0.001					
Psoriatic arthritis	242 (3.6%)	0.53 (0.24)	-0.012 (-0.045, 0.015)	0.55					
Rheumatoid arthritis	1946 (28.7%)	0.36 (0.28)	+0.144 (+0.141, +0.157)	<0.001					
Systemic lupus erythematosus	642 (9.5%)	0.58 (0.21)	-0.073 (-0.087, -0.050)	<0.001					
Systemic sclerosis	433 (6.4%)	0.64 (0.24)	-0.140 (-0.147, -0.122)	<0.001					
Vasculitis	362 (5.3%)	0.65 (0.24)	-0.154 (-0.180, -0.122)	<0.001					

AUC = area under the curve; CDF = cumulative density function; SAPI = standard articles placement index. <sup>a</sup>Positive differences indicate deviations from a uniform distribution above the uniform distribution function (i.e. article placement towards the front of an issue), while negative differences indicate deviations from a uniform distribution below the uniform distribution function  $\frac{1}{2}$  i.e. article placement towards the back of an issue).

#### Articles in the first and last three places of an issue

There were no significant differences in the proportion of articles in the first vs. last three places of an issue for author gender, geographical regions, or industry funding category (Supplementary Table 3). However, consistent with the cumulative distribution function analysis, differences for disease category were observed (Figure 3 and Supplementary **Table 3**). There was a significantly greater proportion of articles in the first three compared to the last three places of an issue for rheumatoid arthritis (35.6% vs. 8.7% P < 0.001) with an OR (95% CI) of 5.77 (4.80, 6.92). There was a similar proportion of articles in the first three and last three places of an issue for ankylosing spondylitis, osteoarthritis, or psoriatic arthritis. There was a significantly lower proportion of articles in the first three compared to the last three places of an issue for crystal arthritis (10.8% vs. 26.8%), other connective tissue diseases (6.8% vs., 16.5%), pediatric rheumatology (8.4% vs. 38.8%), pain syndromes (8.4% vs. 37.1%), systemic lupus erythematosus (4.7% vs. 9.7%), systemic sclerosis (4.4% vs. 18.2%) and vasculitis (6.4% vs. 18.0%) (all P < 0.001). Differences in the proportion of articles in the first vs. last three places of an issue were also observed for research type, with a significantly higher proportion of articles in the first three compared to the last three places of an issue for randomised controlled trials (26.4% vs. 10.9%), systematic literature reviews/meta analyses (24.2% vs. 16.7%) and other clinical research (17.0% vs. 13.6%) (all P < 0.003) and a significantly lower proportion of articles in the first three compared to last three for basic science research (7.6% vs. 26.2% P < 0.001) (Supplementary Table 3).

Comparison of median article placement order rank

*Post hoc* analyses of the differences in median article placement order between genders, geographical regions and industry funding categories and disease categories are shown in

**Supplementary Table 4**. Significant differences in median article placement order were observed between disease categories, with all categories demonstrating greater median article placement order (indicative of placement towards the back of journal issues) compared to rheumatoid arthritis (all P < 0.001).

#### Journals with and without content grouped by disease category

Arthritis & Rheumatology, Seminars in Arthritis and Rheumatism, Arthritis Care & Research and The Journal of Rheumatology grouped issue content by disease category with disease-specific tables of contents sections, while Annals of the Rheumatic Diseases, Rheumatology, and Joint Bone Spine did not group issue content by disease category (Supplementary Table 1). Journals with content grouped by disease showed an association between article placement order and disease category, whereas this was less evident for journals without content grouped by disease (Figure 4). Comparisons between journals with and without content grouped by disease category demonstrated a significant difference in the SAPI distributions for every disease category, with articles on rheumatoid arthritis placed towards the front of issues, and articles on crystal arthritis, pain syndromes, pediatric rheumatology, systemic sclerosis and vasculitis placed towards the end of issues, in journals with content grouped by disease category (Supplementary Table 5).

#### The impact of article placement order on Altmetric scores and downloads

The impact of article placement order was evident in the meta-analysis results, which showed a higher Altmetric score (adjusted for journal) for articles published in the first three places of an issue compared with the last three, (mean difference in Altmetric score of 5.11, 95% CI 1.50, 8.71, Z = 2.78, P = 0.005) (**Figure 5**). The difference in Altmetric scores varied across

different disease categories ( $I^2$  76%; P < 0.001), with the largest difference between positioning in the first three places and positioning in the last three places being observed for articles about rheumatoid arthritis and psoriatic arthritis.

Similarly, meta-analysis showed that articles published in the first three places of an issue had a higher download rate compared to articles in the last three places of an issue (pooled rate difference (95% CI) 442.1 (293.0, 591.2) downloads/article year, Z = 5.81, P < 0.001) (**Figure 5**). The difference in download rate between the first and last three articles was similar across different disease categories ( $I^2$  24%; P = 0.21).

#### **DISCUSSION**

In this analysis of serial rheumatology journals, no relationship between article placement order and author gender, geographical region or industry sponsorship was observed. However, differences for disease category were apparent, with more frequent positioning of articles about rheumatoid arthritis towards the front of journal issues, and articles about crystal arthritis, other connective tissue diseases, pediatric rheumatology, pain syndromes, systemic lupus erythematosus, systemic sclerosis and vasculitis towards the back of issues. Analyses of Altmetric scores and download rates suggested that article placement order influences research prominence, with earlier placed articles receiving more attention.

Medical journals are central to evidence-based practice and represent a key source of new knowledge for medical professionals.[21, 22] Unbiased publication practices are important in allowing a variety of perspectives and emphases to expand the scope of research and clinical practice. Although bias has been previously reported in academic journals based on authorship ordering of genders,[9, 10] representation of geographical regions,[9, 11] and acceptance and time to publication based on industry sponsorship,[12] our analysis showed

that these factors were not associated with article placement order within serial rheumatology journals.

Articles about rheumatoid arthritis were preferentially placed towards the front of rheumatology journals, while other conditions, particularly pain syndromes, crystal arthritis, pediatric syndromes, and connective tissue diseases, were ordered towards the back. Rheumatoid arthritis was the disease category with the greatest number of articles, therefore giving it the greatest opportunity to be listed first, but our analyses accounted for the variation in article numbers between disease categories. Although rheumatoid arthritis is a very important rheumatic disease, [23] general rheumatology practice involves the diagnosis and treatment of a wide range of diseases.[24, 25] General rheumatology journals should ideally reflect that diversity of clinical practice. A similar distribution of articles on each disease category would therefore be expected if there was no bias for disease category. The reason for the observed differences in article placement for disease category is unclear. Disease privileging in other fields of medical research has been reported, with some prevalent diseases with high global impact being under-funded and under-researched.[13-15] Crystal arthritis, osteoarthritis and pain syndromes are common; for example, prevalence estimates for US adults for gout are 3.9%, [26] for osteoarthritis are 13.4%, [27] and for low back pain are 26.4%.[28] However, these conditions may be viewed by rheumatologists and journal editors as less important or less severe. [29, 30] Our analysis of article placement order, which did not reflect prioritising of diseases based on epidemiology or severity, emphasises the disconnect between the prevalence of disease and health research. These perceptions of some rheumatic diseases have the potential to impact attitudes in clinical practice and contribute to lower quality of care.[30, 31] Rheumatic diseases such as vasculitis, pediatric rheumatic disease, and scleroderma are less common, but can lead to major morbidity and reduced

quality of life. Improving the impact and accessibility of research published on 'lower

priority' or less common rheumatic diseases may have an important impact on clinicians' understanding about and attitudes towards these conditions in clinical practice. Differences in article placement order for disease category was particularly evident in journals with disease-specific tables of contents sections within issues, rather than journals that did not group issue content by disease category. It has been suggested that grouping article content by disease category may improve the reader experience.[32] However, such decisions have the potential to further reduce readers' exposure to diseases that are already under-studied or less well understood. Editorial decisions to remove grouping by disease category, or to cycle the order of disease category groups for each issue may be a simple solution to overcome bias for disease category reflected in article placement order. In our analysis, articles appearing in the first three places of an issue had higher Altmetric scores and download rates compared to articles appearing in the last three places of an issue. This is consistent with prior studies which also demonstrate the impact of the primacy effect on research prominence. [6-8] Collectively, these findings indicate that articles placed at the front of journal issues receive greater prominence. The prominence and impact of research published in journals has an important role in not only providing information to improve knowledge and treatment, but also in financing further research[33] and obtaining academic promotion.[34] The current analysis has some limitations. Firstly, Altmetric and download data were not available from all journals included in the analysis, and it is unclear whether similar differences are present across all journals. Secondly, citation rates were not evaluated because of the short time period between article publication and data extraction which would not have reflected true citation rates, which increase over time. Finally, this analysis did not explore other factors that may have contributed to article placement order such as quality, impact, or

originality of the study, or the presence of prolific or "star" authors.[35] Further research may also focus on identifying factors influencing editorial decisions about the placement order of articles about different diseases. For example, we did observe that basic science articles were placed towards the back of an issue, suggesting that editors prioritise clinical research over laboratory-based research. A strength of this paper is the use of multiple methods of analysis to explore the relationship between disease category and article placement order, including an analysis of the distribution of article placement, an analysis of the difference in proportion of articles appearing in the first and last three places of an issue, and an analysis of the comparison of median article placement order between disease categories. Collectively, these results provide robust and detailed evidence that bias for certain disease categories is reflected in article placement order.

In conclusion, author gender, geographical region, or funding source do not influence article placement order in serial rheumatology journals. However, bias for certain disease categories is reflected in article placement order. Article placement order may have an impact on research prominence, including Altmetric scores and download rate. Editorial choices about the serial position of articles within journals can influence prioritisation of certain diseases.

Acknowledgements

None.

#### **Competing interests**

ND has received consulting fees, speaker fees or grants from AstraZeneca, Horizon, Amgen, Arthrosi, Dyve Biosciences, Hengrui, Abbvie, Pfizer, and Janssen, outside the submitted work. ND and SS work primarily in the field of gout research (a condition that was analysed in this research project). GG and AG declare no competing interests.

#### **Funding**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

#### **Author contributions**

SS contributed towards acquisition, analysis and interpretation of the data. GG contributed towards design of the study and analysis and interpretation of the data. AG contributed towards design of the study and interpretation of the data. ND contributed towards design of the study, and acquisition and interpretation of the data. All authors were involved in drafting of the work or revising it critically for important intellectual content. All authors approved the final version to be published and agree to be accountable for all aspects of the work.

#### Data statement

407 All extracted data used in the analyses are available upon reasonable request from the

408 corresponding author.

TO BEEL TOUR ONL

REF	ERE	ENCES	5
-----	-----	-------	---

- [1] Chen E, Simonovits G, Krosnick JA, Pasek J. The impact of candidate name order on election outcomes in North Dakota. *Elect Stud* 2014;35:115–22.
- 414 [2] Becker SL. Why an order effect? *Public Opin Q* 1954;18:271–8.
- [3] Mantonakis A, Rodero P, Lesschaeve I, Hastie R. Order in choice: effects of serial position on preferences. *Psychol Sci* 2009;20:1309–12.
- [4] Eysenbach G, Köhler C. How do consumers search for and appraise health information on the world wide web? Qualitative study using focus groups, usability tests, and in-depth interviews. *BMJ* 2002;324:573–7.
- [5] Haque A-u, Ginsparg P. Positional effects on citation and readership in arXiv. *J Assoc Inf* Sci Technol 2009;60:2203–18.
- [6] Novarese M, Wilson CM. Being in the right place: a natural field experiment on list
   position and consumer choice. MPRA Paper 48074, University Library of Munich,
   Germany; 2013.
- 425 [7] Jonah B. Does presentation order impact choice after delay? *Top Cogn Sci* 2016;8:670–426 84.
- [8] Feenberg D GI, Gaule P, Gruber J. It's Good to be First: Order Bias in Reading and Citing NBER Working Papers. *Rev Econ Stat* 2015;99:32–9.
- [9] Filardo G, da Graca B, Sass DM, Pollock BD, Smith EB, Martinez MA-M. Trends and comparison of female first authorship in high impact medical journals: observational study (1994-2014). *BMJ* 2016;352:i847.
- West JD, Jacquet J, King MM, Correll SJ, Bergstrom CT. The role of gender in scholarly authorship. *PLoS One* 2013;8:e66212.

Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship

- Edwards HA, Schroeder J, Dugdale HL. Gender differences in authorships are not associated with publication bias in an evolutionary journal. *PLoS One* 2018;13:e0201725.
- and research outcome and quality: systematic review. *BMJ* 2003;326:1167–70.
- 438 [13] Yegros A, Tijssen R, Abad-García M-F, Ràfols I. Drug research priorities at odds
- with global disease toll [Blog]. Nature Index 2018. Accessed on 6/8/2019 from:
- https://www.natureindex.com/news-blog/drug-research-priorities-at-odds-with-global-
- 441 disease-toll

[12]

- 442 [14] Lobner K, Lanzkron S, MHS, Haywood C. NIH and National Foundation
- expenditures for sickle cell disease and cystic fibrosis are associated with Pubmed
- publications and FDA approvals. *Blood* 2013;122:1739.
- 445 [15] Catalá-López F, García-Altés A, Álvarez-Martín E, Gènova-Maleras R, Morant-
- Ginestar C. Does the development of new medicinal products in the European Union
- address global and regional health concerns? *Popul Health Metr* 2010;8:34-43.
- 448 [16] Micceri T. The unicorn, the normal curve and other improbable creatures. *Psychol*
- *Bull* 1989;105:156-66.
- 450 [17] Altman DG, Bland JM. How to obtain the P value from a confidence interval. BMJ
- 451 2011;343:d2304.
- 452 [18] Bolland MJ, Gamble GD, Avenell A, Grey A, Lumley T. Baseline P value
- distributions in randomized trials were uniform for continuous but not categorical
- 454 variables. *J Clin Epidemiol* 2019;112:67-76.
- 455 [19] Storey JD, Tibshirani R, Statistical significance for genomewide studies. *Proc of the*
- *Nat Acady Sci U S A* 2003;100:9440-5.

- 457 [20] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
  458 powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* 1995;57:289–
  459 300.
- Laine C, Weinberg D. How can physicians keep up-to-date? *Annu Rev Med* 1999;50:99–110.
- Sackett DL, Rosenberg WM. The need for evidence-based medicine. *JRSM* 1995;88:620–4.
- Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73:1316–22.
- 166 [24] Ng X, Low AHL, Chew L-C, et al. Disease patterns of rheumatology outpatients seen
   in a tertiary hospital serving a multi-ethnic, urban Asian population in Singapore. *Int J* Rheum Dis 2013;16:273–8.
- 469 [25] Miedema HS, van der Linden SM, Rasker JJ, Valkenburg HA. National database of 470 patients visiting rheumatologists in The Netherlands: the standard diagnosis register of 471 rheumatic diseases. A report and preliminary analysis. *Rheumatol* 1998;37:555–61.
- Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general
   population: The National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011;63:3136-41.
- [27] Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative
   methods for defining osteoarthritis and the impact on estimating prevalence in a US
   population-based survey. *Arthritis Care Res* 2016;68:574-80.
- Deyo RA, Mirza SK, Martin BI, Back pain prevalence and visit rates: estimates from U.S. national surveys 2002. *Spine* 2006;31:2724-7.
- Birrell F, Arden NK, Conaghan PG, Cooper C, Dieppe P, Doherty M. Is it time for more rheumatologists to embrace osteoarthritis? *Rheumatol* 2005;44:829-30.

482	[30]	Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269–
183	70	

- [31] Chua JR, Jamal S, Riad M, et al. Disease burden in osteoarthritis is similar to that of rheumatoid arthritis at initial rheumatology visit and significantly greater six months later.
- *Arthritis Rheumatol* 2019; doi: 10.1002/art.40869
- 487 [32] Smolen JS. Greetings from the editor 2019. Ann Rheum Dis 2019;78:1–2.
- 488 [33] Cabezas-Clavijo Á, Robinson-García N, Escabias M, Jiménez-Contreras E.
- Reviewers' ratings and bibliometric indicators: hand in hand when assessing over
- research proposals? *PLoS One* 2013;8:e68258.
- Holden G, Rosenberg G, Barker K. Bibliometrics: a potential decision making aid in
- hiring, reappointment, tenure and promotion decisions. Soc Work Health Care
- 493 2005;41:67–92.
- 494 [35] Tomkins A, Zhang M, Heavlin WD. Reviewer bias in single- versus double-blind
- 495 peer review. *Proc Natl Acad Sci U S A* 2017;114:12708-1

#### Figure legends


**Figure 1.** Cumulative distribution function plots of standardised article placement indices (SAPI) for first author gender (**A.**), senior author gender (**B.**), industry funding (**C.**), and first author's geographic region of affiliated institution (**D.**). Left deviated distributions suggest prioritisation towards the front of journal issues.


**Figure 2.** Cumulative distribution function plots of standardised article placement indices (SAPI) for each disease category. Left deviated distributions suggest prioritisation towards the front of journal issues.


**Figure 3.** Percentage of articles (per disease category) published in first three and last three places of an issue (*P*-values indicate difference between proportions of articles in first and last three places of an issue).


**Figure 4.** Cumulative distribution function plots of standardised article placement indices (SAPI) for each disease category for journals with (**A.**) and without (**B.**) contents grouped by disease. Left deviated distributions suggest prioritization towards the front of journal issues.

**Figure 5.** Forest plots showing the mean differences for each disease category for Altmetric scores (**A.**) and download rates (**B.**) between articles published in the first vs. last three places of an issue. Positive differences indicate a higher Altmetric score/download rate for articles published in one of the first three places of an issue. Differences in Altmetric scores are adjusted for journal. Download data was available from one journal. CTD: connective tissue disease.












For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# A. Journals with issue content grouped by disease



## B. Journals without issue content grouped by disease





## BMJ Open A. Differences in Altmetric scores between articles in first and last three places of an issee

Ankylosing spondylitis 14	<b>Mean score</b> 4.19	N	Mean score	N	Weight	difference	95% CI	analysis, 95% CI
, 0, ,	4 19					uniterence	2270 CI	ailalysis, 5570 Ci O
Crystal arthritis 9	1.10	32	6.10	31	7.44%	8.09	(-0.70, 16.88)	
Ciystai ai tiii tis 3.	.10	21	25.23	39	2.90%	-16.14	(-34.85, 2.58)	<del></del>
Miscellaneous 10	0.95	20	4.18	50	9.93%	6.77	(0.99, 12.55)	
Not disease-specific 28	8.47	36	7.73	66	2.40%	20.74	(-0.33, 41.82)	June
Osteoarthritis 18	8.47	47	20.26	47	4.20%	-1.79	(-16.35, 12.77)	<u>-</u> + ≥
Other CTDs 6.	.421	19	3.57	47	11.91%	2.85	(-0.58, 6.27)	2020.
Pediatric rheumatology 7.	.14	29	5.57	86	11.63%	1.57	(-2.21, 5.35)	
Pain syndromes 48	8.36	11	26.10	29	0.61%	22.26	(-22.78, 67.30)	<del> </del>
Psoriatic arthritis 13	3.00	17	3.00	17	8.38%	13.06	(5.46, 20.65)	- <b>■</b> -
Rheumatoid arthritis 24	4.16	434	4.03	156	9.01%	20.13	(13.29, 26.97)	🕳 ) 등
ystemic lupus erythematosus 12	2.59	27	7.69	58	7.69%	4.90	(-3.55, 13.36)	<del>  -</del> 8
Systemic sclerosis 3,	.88	17	2.81	69	12.50%	1.07	(-1.49, 3.63)	<b>•</b>
Vasculitis 2.	.68	22	4.41	37	11.42%	-1.72	(-5.77, 2.33)	ownloaded from
Total		732		732	100.0	5.11	(1.50, 8.71)	-40 -20 0 20 40 60

Test for overall effect: Z = 2.78; P = 0.005

Last three First three places of an issue

	First three		Last three		Rate			Mean difference, random		
_	Mean score	N	Mean score	N	Weight	difference	95% CI	effects analysis, 95% Cl		
Ankylosing spondylitis	842.8	17	344.9	10	10.9%	497.9	(115.6, 880.3)	20		
Crystal arthritis	726.3	9	198.1	5	8.88%	528.3	(89.2, 967.3)	2024		
Miscellaneous	1073.5	7	385.3	12	5.18%	688.1	(78.7, 1297.6)	<del></del> by		
Not disease-specific	1430.0	15	336.0	15	1.95%	1093.9	(54.7, 2133.1)			
Osteoarthritis	465.5	13	457.2	22	12.04%	8.2	(-347.9, 364.4)	_ <del>+</del> _ ≌		
Other CTDs	785.3	5	389.1	14	8.40%	396.2	(-58.7, 851.1)	guest.		
Pediatric rheumatology	758.2	6	626.0	4	3.07%	132.2	(-683.7, 948.1)			
Pain syndromes	1110.5	3	346.4	1	0.00%	Excluded		Prot		
Psoriatic arthritis	1408.0	14	491.8	3	1.20%	916.2	(-426.3, 2258.7)			
Rheumatoid arthritis	952.2	76	358.8	54	24.23%	593.4	(409.2, 777.6)	cted by		
ystemic lupus erythematosus	880.0	11	538.7	12	10.36%	341.3	(-54.6, 737.2)	<del>  ■                                   </del>		
Systemic sclerosis	480.6	5	286.8	25	9.19%	193.9	(-235.4, 623.1)	<del> ■</del> ×		
Vasculitis	961.3	3	142.0	6	4.59%	819.3	(165.95, 1472.7)	— 🗝 👸		
Total		183		184	100.0	442.1	(293.0, 591.2)	copyright.		

Heterogeneity: Tau² = 15400; Chi² = 14.4; l² = 23.7% (P = 0.211)

Fresper Venirem y = 5 to point pen.bmj.com/site/about/guidelines.xhtml Last three

First three

#### SUPPLEMENTARY MATERIAL

Supplementary Tables

**Supplementary Table 1. Journal characteristics** 

	Publisher	Country of publication	2016 Impact Factor	Relevant affiliated society	Issues per	Sontents Fourtents Frouped by	Total number of articles included, n	Number of included articles per issue, mean (SD)
Annals of the Rheumatic Diseases	BMJ Publishing Group Ltd	United Kingdom	12.811	European League Against Rheumatism	12	<b>8</b> 0 <b>⇒</b>	1374	13.2 (9.4)
Arthritis & Rheumatology	John Wiley & Sons	United States	6.918	American College of Rheumatology	12	from h	1367	12.5 (7.6)
Rheumatology	Oxford University Press	United Kingdom	4.818	British Society for Rheumatology	12	<b>₹</b> 0	1158	10.2 (5.7)
Seminars in Arthritis and Rheumatism	Elsevier	United States	4.498	None	6	es O	403	7.3 (4.1)
Joint Bone Spine	Elsevier	United States	3.329	French Society of Rheumatology	6	jo <b>z</b> en.	239	4.6 (2.6)
Arthritis Care & Research	John Wiley & Sons	United States	3.319	American College of Rheumatology, Association of Rheumatology Health Professionals	12	es J. co	1098	9.6 (5.4)
The Journal of Rheumatology	Journal of Rheumatology Publishing Company Limited	Canada	3.150	Canadian Rheumatology Association	12	on ≱es o	1148	10.3 (6.1)

Supplementary Table 2. Number of articles within each disease category for crystal arthritis, miscellaneous and other connective tissue diseases

other connective dissue diseases	Frequency	Percent
Crystal arthritis (n = 269)		
Gout	260	96.7
Calcium crystal diseases	9	3.3
Miscellaneous Disease (n = 277 articles)		
Regional musculoskeletal syndromes	48	17.3
Osteoporosis	22	7.9
IgG4-related disease	20	7.2
FMF	20	7.2
Polymyalgia rheumatica	19	6.9
CAPS	16	5.8
Still's disease	10	3.6
Septic arthritis	8	2.9
Fibrosis	8	2.9
Sarcoidosis	7	2.5
Chikungunya Virus	7	2.5
SAPHO syndrome	6	2.2
TRAPS	5	1.8
Polychondritis	5	1.8
Ehlers-Danlos Syndrome	4	1.4
CAPS Still's disease Septic arthritis Fibrosis Sarcoidosis Chikungunya Virus SAPHO syndrome TRAPS Polychondritis Ehlers-Danlos Syndrome Lyme disease Alkaptonuria Hemophagocytic syndromes Vertebral fractures Uveitis Undifferentiated arthritis Tuberculosis Periodic fever syndrome Löfgren syndrome Erdheim-Chester disease	4	1.4
Alkaptonuria	4	1.4
Hemophagocytic syndromes	3	1.1
Vertebral fractures	2	0.7
Uveitis	2	0.7
Undifferentiated arthritis	2	0.7
Tuberculosis	2	0.7
Periodic fever syndrome	2	0.7
Löfgren syndrome	2	0.7
Erdheim-Chester disease	2	0.7
Dupuytren's disease	2	0.7
ACPA-negative undifferentiated arthritis	1	0.4
Yellow fever	1	0.4
Whipple disease	1	0.4
Vertebral endplate lesions	1	0.4
Tumoral calcinosis	1	0.4
Tenosynovial giant cell tumor	1	0.4
Systemic autoinflammatory disease (SAID)	1	0.4
Schnitzler's syndrome	1	0.4
Ribbing disease	1	0.4
Receptor-associated periodic syndrome	1	0.4
Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome	1	0.4
Pyogenic arthritis	1	0.4
Primary angiitis of the CNS	1	0.4
Preeclampsia	1	0.4
Pigmented villonodular synovitis	1	0.4
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA)	1	0.4
syndrome		

Palindromic rheumatism         1         0.4           Paget's disease         1         0.4           Osteomyelitis         1         0.4           NOD2-associated autoinflammatory diseases         1         0.4           Muckle-wells syndrome         1         0.4           Mikulicz's disease         1         0.4           Mevalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Medial meniscal tears         1         0.4           Medarophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Ebola virus         1         0.4           Ebola virus         1         0.4           Chronic graft-versus-host disease <th>Paraneoplastic rheumatic syndrome</th> <th>1</th> <th>0.4</th>	Paraneoplastic rheumatic syndrome	1	0.4
Osteonecrosis         1         0.4           Osteomyelitis         1         0.4           NOD2-associated autoinflammatory diseases         1         0.4           Muckle-wells syndrome         1         0.4           Mikulicz's disease         1         0.4           Mevalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Febroal fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis	Palindromic rheumatism	1	0.4
Osteomyelitis         1         0.4           NOD2-associated autoinflammatory diseases         1         0.4           Muckle-wells syndrome         1         0.4           Mikulic2's disease         1         0.4           Medalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Febroral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host	Paget's disease	1	0.4
NOD2-associated autoinflammatory diseases         1         0.4           Muckle-wells syndrome         1         0.4           Mikulicz's disease         1         0.4           Mevalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Biphosphate	Osteonecrosis	1	0.4
Muckle-wells syndrome         1         0.4           Mikulicz's disease         1         0.4           Mevalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Febroal fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1 </td <td>Osteomyelitis</td> <td>1</td> <td>0.4</td>	Osteomyelitis	1	0.4
Mikulicz's disease         1         0.4           Mevalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Febroral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Ebola virus         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4	NOD2-associated autoinflammatory diseases	1	0.4
Mevalonate kinase deficiency         1         0.4           Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary necurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Ebola virus         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Aicardi-Goutières syndrome         1         0.4 <td>Muckle-wells syndrome</td> <td>1</td> <td>0.4</td>	Muckle-wells syndrome	1	0.4
Medial meniscal tears         1         0.4           Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Biphosphate trochanteric fracture         1         0.4           Aicardi-Goutières syndrome         1         0.4           Other connective tissue disease (n = 339 articles	Mikulicz's disease	1	0.4
Macrophage activation syndrome         1         0.4           Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary heemochromatosis         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Amyloidosis         1         0.4           Aicardi-Goutières syndrome         1         0.4           Other connective tissue disease (n = 339 articles)	Mevalonate kinase deficiency	1	0.4
Leri's pleonosteosis         1         0.4           Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Amyloidosis         1         0.4           Aicardi-Goutières syndrome         1         0.4           Other connective tissue disease (n = 339 articles)           Sjogren's syndrome         174         51.3	Medial meniscal tears	1	0.4
Kikuchi-Fujimoto disease         1         0.4           Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Febry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Blau syndrome         1         0.4           Bhybosphate trochanteric fracture         1         0.4           Amyloidosis         1         0.4           Accardi-Goutières syndrome         1         0.4           Other connective tissue disease (n = 339 articles)           Sjogren's syndrome         174         <	Macrophage activation syndrome	1	0.4
Joint hypermobility syndrome         1         0.4           Immune reconstitution inflammatory syndrome         1         0.4           Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Biphosphate trochanteric fracture         1         0.4           Amyloidosis         1         0.4           Aicardi-Goutières syndrome         1         0.4           Other connective tissue disease (n = 339 articles)           Sjogren's syndrome         174         51.3           Inflammatory myositis         115         33.9           Antiphospholipid syndrome         41         12.1           Mixed connective tissue disease<	Leri's pleonosteosis	1	0.4
Immune reconstitution inflammatory syndrome       1       0.4         Hereditary recurrent fever syndromes       1       0.4         Hereditary haemochromatosis       1       0.4         Haploinsufficiency of A20       1       0.4         Glomerulonephritis       1       0.4         Gaucher disease       1       0.4         Femoral fractures       1       0.4         Fabry disease       1       0.4         Ebola virus       1       0.4         Discitis       1       0.4         Chronic graft-versus-host disease       1       0.4         Blau syndrome       1       0.4         Blau syndrome       1       0.4         Amyloidosis       1       0.4         Anicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Kikuchi-Fujimoto disease	1	0.4
Hereditary recurrent fever syndromes         1         0.4           Hereditary haemochromatosis         1         0.4           Haploinsufficiency of A20         1         0.4           Glomerulonephritis         1         0.4           Gaucher disease         1         0.4           Femoral fractures         1         0.4           Fabry disease         1         0.4           Ebola virus         1         0.4           Discitis         1         0.4           Chronic graft-versus-host disease         1         0.4           Blau syndrome         1         0.4           Biphosphate trochanteric fracture         1         0.4           Amyloidosis         1         0.4           Aicardi-Goutières syndrome         1         0.4           Other connective tissue disease (n = 339 articles)         1         0.4           Sjogren's syndrome         174         51.3           Inflammatory myositis         115         33.9           Antiphospholipid syndrome         41         12.1           Mixed connective tissue disease         7         2.1           CTD-associated interstitial lung disease         1         0.3	Joint hypermobility syndrome	1	0.4
Hereditary haemochromatosis       1       0.4         Haploinsufficiency of A20       1       0.4         Glomerulonephritis       1       0.4         Gaucher disease       1       0.4         Femoral fractures       1       0.4         Fabry disease       1       0.4         Ebola virus       1       0.4         Discitis       1       0.4         Chronic graft-versus-host disease       1       0.4         Blau syndrome       1       0.4         Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Immune reconstitution inflammatory syndrome	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Hereditary recurrent fever syndromes	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Hereditary haemochromatosis	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Haploinsufficiency of A20	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Glomerulonephritis	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Gaucher disease	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Femoral fractures	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Fabry disease	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Ebola virus	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Discitis	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Chronic graft-versus-host disease	1	0.4
Biphosphate trochanteric fracture       1       0.4         Amyloidosis       1       0.4         Aicardi-Goutières syndrome       1       0.4         Other connective tissue disease (n = 339 articles)         Sjogren's syndrome       174       51.3         Inflammatory myositis       115       33.9         Antiphospholipid syndrome       41       12.1         Mixed connective tissue disease       7       2.1         CTD-associated interstitial lung disease       1       0.3	Blau syndrome	1	0.4
Aicardi-Goutières syndrome 1 0.4  Other connective tissue disease (n = 339 articles)  Sjogren's syndrome 174 51.3  Inflammatory myositis 115 33.9  Antiphospholipid syndrome 41 12.1  Mixed connective tissue disease 7 2.1  CTD-associated interstitial lung disease 1 0.3	Biphosphate trochanteric fracture	1	0.4
Other connective tissue disease (n = 339 articles)Sjogren's syndrome17451.3Inflammatory myositis11533.9Antiphospholipid syndrome4112.1Mixed connective tissue disease72.1CTD-associated interstitial lung disease10.3	Amyloidosis	1	0.4
Sjogren's syndrome17451.3Inflammatory myositis11533.9Antiphospholipid syndrome4112.1Mixed connective tissue disease72.1CTD-associated interstitial lung disease10.3	Aicardi-Goutières syndrome	1	0.4
Inflammatory myositis Antiphospholipid syndrome 41 12.1 Mixed connective tissue disease 7 2.1 CTD-associated interstitial lung disease 1 0.3	Other connective tissue disease (n = 339 articles)		
Antiphospholipid syndrome 41 12.1 Mixed connective tissue disease 7 2.1 CTD-associated interstitial lung disease 1 0.3	Sjogren's syndrome	174	51.3
Mixed connective tissue disease 7 2.1 CTD-associated interstitial lung disease 1 0.3	Inflammatory myositis	115	33.9
CTD-associated interstitial lung disease 1 0.3	Antiphospholipid syndrome	41	12.1
	Mixed connective tissue disease	7	2.1
Undifferentiated connective tissue disease 1 0.3	CTD-associated interstitial lung disease	1	0.3
	Undifferentiated connective tissue disease	1	0.3

BMJ Open

BMJ Open

Supplementary Table 3. Number of articles appearing in at least one article in first and last three articles of an issue for author gender, geographical region of affiliated institution, industry funding category, and disease category

funding category, and disease category

	Total articles	First thro	ee % of total	Last the	ree % of total	Odds ratio (OR) <sup>a</sup>	→ 95% CI for OR	$P^{ m b}$
First author gender		IN	76 OI tOtal	IN	70 OI LOTAI	(OK)		
First author gender Female	3517	537	15.3%	586	16.7%	0.90	Φ 0.79, 1.02	0.17
Male	3250	557 557	17.1%	509	15.7%	1.11	0.79, 1.02 0.98, 1.27	0.17
Last author gender	3230	331	17.170	309	13.770	1.11	0.96, 1.27 N	0.17
Female	2359	393	16.7%	355	15.0%	1.13	0.97, 1.32	0.17
Male	4412	705	16.0%	737	16.7%	0.95	0.97, 1.32	0.17
Geographical region of affiliated institution	4412	703	10.0%	131	10.7%	0.93		0.57
8 1							0.88, 1.21 0.00 0.91, 1.18	
(first author)	0177	262	1.6.60/	252	1.6.00/	1.02	<b>D</b>	0.60
North America	2177	362	16.6%	352	16.2%	1.03	0.88, 1.21	0.68
Europe	3486	573	16.4%	556	16.0%	1.04		0.68
Other	1124	163	14.5%	190	16.9%	0.83	₹ 0.66, 1.05	0.35
Industry funding							Ĭ	
Industry-funded and initiated	640	104	16.3%	109	17.0%	0.95	<b>⇒</b> 0.70, 1.27	0.71
Industry-funded and investigator-initiated	596	87	14.6%	111	18.6%	0.75	<b>₹</b> 0.55, 1.01	0.09
Not industry-funded	5551	907	16.3%	878	15.8%	1.04	0.94, 1.15	0.09
Research type							on	
Randomised controlled trials	488	129	26.4%	53	10.9%	2.95	3. 2.08, 4.18	< 0.001
Systematic literature reviews / meta-analyses	438	106	24.2%	73	16.7%	1.60	1.14, 2.23	0.003
Other clinical research	4466	757	17.0%	606	13.6%	1.30		< 0.001
Basic science	1395	106	7.6%	366	26.2%	0.23	0.18, 0.29	< 0.001
Disease category							<del></del>	
Ankylosing spondylitis	496	47	9.5%	40	8.1%	1.19	0.77, 1.86 0.21, 0.53	0.51
Crystal arthritis <sup>c</sup>	269	29	10.8%	72	26.8%	0.33	0.21, 0.53	< 0.001
Miscellaneous	277	28	10.1%	103	37.2%	0.19	9 0.12, 0.30	< 0.001
Not disease-specific	422	52	12.3%	121	28.7%	0.35	> 0.24, 0.50	< 0.001
Osteoarthritis	773	81	10.5%	82	10.6%		0.71, 1.37	0.934
Other connective tissue diseases	339	23	6.8%	56	16.5%	0.37	3. 0.22, 0.61	< 0.001
Pediatric rheumatology	443	37	8.4%	172	38.8%	0.14	o 0.10, 0.21	< 0.001
Pain syndromes	143	12	8.4%	53	37.1%	0.14	N 0.08, 0.31	< 0.001
Psoriatic arthritis <sup>c</sup>	242	26	10.7%	23	9.5%	1.15	0.63, 2.07	0.71
Rheumatoid arthritis	1946	692	35.6%	170	8.7%	5.77	4.80, 6.92	<0.001
Systemic lupus erythematosus	642	30	4.7%	62	9.7%		0.29, 0.72	0.001
Systemic sclerosis	433	18	4.4%	79	18.2%		9 0.11, 0.33	< 0.001
Vasculitis	433 362	23	4.4% 6.4%	65	18.2%	0.19	© 0.11, 0.33 Ø 0.19, 0.51	<0.001
"The odds of being in at least one article in the							ζ, 0.127, 0.12 I	

Vasculitis

362
23
6.4%
65
18.0%
0.31
90.19,0.51

<a href="https://docs.org/linear-to-tal-englished-li

6/bmjopen-2019-0:

Supplementary Table 4. Compariso	on of median article placement order between gend	lers of first and last authors, geographical regions, industry f	funding categories and disease
categories.			55
	Article placement order	P for difference in medians <sup>a</sup>	Ö

categories.				<u><u> </u></u>
	Article placement orde		P for difference in medians	S <sup>a</sup> O
	Median (IQR)	Min-max		on
First author gender				17
Female	10 (10)	1-45	0.643	•
Male	10 (10)	1-49	0.043	Jur
Last author gender				Ō
Female	10 (10)	1-46	0.017	20
Male	10 (10)	1-49	0.017	2020
Geographical region				- -
North America	10 (10)	1-48		Downlo
Europe	10 (10)	1-49	0.906	\$
Other	10 (10)	1-47		Ō
Industry funding				aded
Not industry funded	10 (10)	1-48		Q.
Industry funded and initiated	8 (10)	1-48	< 0.001	fron
Industry funded and investigator initiated	8 (9)	1-42		mo
Disease category				P for comparison with rheumatoid arthritis <sup>b</sup>
Ankylosing spondylitis	9 (7)	1-40		<0.001
Crystal arthritis	12 (10)	1-38		<0.001
Miscellaneous	13 (10)	1-49		<0.001
Not disease-specific	11 (10)	1-43		<0.001
Osteoarthritis	10 (8)	1-42		<0.001
Other connective tissue diseases	12 (9)	1-47		<0.001
Paediatric rheumatology	14 (11)	1-35	< 0.001	<0.001
Pain syndromes	13 (9)	1-32		<0.001
Psoriatic arthritis	10 (7)	1-45		<0.001
Rheumatoid arthritis	5 (8)	1-48		<0.001
Systemic lupus erythematosus	12 (7)	1-41		<0.001
Systemic sclerosis	13 (9)	1-45		<0.001
Vasculitis	13 (9)	1-39		<0.001
aVmalal Wallia on Monn Whitney II toota on		II 44-		<u></u>

<sup>&</sup>lt;sup>a</sup>Kruskal Wallis or Mann-Whitney U tests, as appropriate; <sup>b</sup>Mann-Whitney U tests


BMJ Open

BMJ Open

Supplementary Table 5. Difference in cumulative density function distribution of standard article placement indices (SAPI) between journals with and without contents grouped by disease for articles with related editorials and for each disease category. articles with related editorials and for each disease category

	Journals with co	ntents not group	ed by disease	Journals with co	ntents grouped	by disease	Two-sample Kolm	ogorov-Smirnov Z test <sup>b</sup>
	N (%)	SAPI <sup>a</sup>		N (%)	<b>SAPI</b> <sup>a</sup>		Effect size (D)	FDR-adjusted P
		Mean	SD		Mean	SD	7 J	
Ankylosing spondylitis	228 (8.2%)	0.49	0.28	268 (6.7%)	0.52	0.19	0.20	< 0.001
Crystal arthritis	137 (4.9%)	0.49	0.28	132 (3.3%)	0.78	0.20	0.50	< 0.001
Miscellaneous	152 (5.5%)	0.62	0.30	125 (3.1%)	0.76	0.26	0.29	< 0.001
Not disease-specific	178 (6.4%)	0.53	0.30	244 (6.1%)	0.66	0.29	0.22	< 0.001
Osteoarthritis	231 (8.3%)	0.55	0.27	542 (13.5%)	0.47	0.22	0.20	< 0.001
Other connective tissue diseases	167 (6.0%)	0.49	0.29	172 (4.3%)	0.70	0.17	0.36 o	< 0.001
Pediatric rheumatology	121 (4.4%)	0.48	0.26	322 (8.0%)	0.77	0.25	0.50	< 0.001
Pain syndromes	41 (1.5%)	0.54	0.35	102 (2.5%)	0.75	0.21	0.36 큥	0.001
Psoriatic arthritis	109 (3.9%)	0.48	0.27	133 (3.3%)	0.56	0.20	0.22	0.005
Rheumatoid arthritis	881 (31.8%)	0.51	0.29	1065 (26.5%)	0.23	0.20	0.49	< 0.001
Systemic lupus erythematosus	193 (7.0%)	0.56	0.28	449 (11.2%)	0.58	0.17	0.19	< 0.001
Systemic sclerosis	182 (6.6%)	0.60	0.30	251 (6.3%)	0.68	0.18	0.26 💆	< 0.001
Vasculitis	151 (5.4%)	0.51	0.28	211 (5.3%)	0.75	0.14	0.50	< 0.001

<sup>\*</sup>Lower SAPI scores equate to articles ordered at the front of issues, while higher SAPI scores equate to articles ordered at the end of issues. \*Test of difference in distribution of SAPI between journals with and without contents grouped by disease sections. Bolded P-values indicated significant difference at < 0.05.



**Supplementary Figure 1.** Cumulative distribution function plots of standardised article placement indices (SAPI) for research types. Left deviated distributions suggest prioritisation towards the front of journal issues.

# **BMJ Open**

## Article Placement Order in Rheumatology Journals: A Content Analysis

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-034550.R2
Article Type:	Original research
Date Submitted by the Author:	25-Feb-2020
Complete List of Authors:	Stewart, Sarah; The University of Auckland, Medicine Gamble, Greg; University of Auckland, Department of Medicine Grey, Andrew; University of Auckland Dalbeth, Nicola; University of Auckland,
 b>Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Evidence based practice
Keywords:	publication, bias, RHEUMATOLOGY

SCHOLARONE™ Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

- 1 Article Placement Order in Rheumatology Journals: A Content Analysis
- 2 Sarah Stewart<sup>1</sup>, PhD
- 3 Greg Gamble<sup>1</sup>, MSc
- 4 Andrew Grey<sup>1</sup>, MD
- 5 Nicola Dalbeth<sup>1, 2</sup>, MD
- <sup>1</sup> School of Medicine, The University of Auckland, 85 Park Road, Grafton, Auckland 1062,
- 8 New Zealand
- <sup>2</sup> Corresponding author: School of Medicine, The University of Auckland, 85 Park Road,
- Grafton, Auckland 1062, New Zealand; n.dalbeth@auckland.ac.nz; +64 9 923 2568
- **12 Word count:** 3980

- 14 Abstract
- **Objectives.** To analyse variables associated with article placement order in serial
- 16 rheumatology journals.
- **Design.** Content analysis.
- Setting. Original articles published in seven rheumatology journals from 2013-2018.
- **Primary and secondary outcome measures**. The following data were extracted from 6,787
- articles: order number of article in issue, gender of first and last author, geographical region,
- 21 industry funding, research design, and disease category. Cumulative density function plots
- 22 were used to determine whether article placement distribution was different from the
- expected distribution. Odds ratios for articles published in the first three places of an issue
- compared with the last three places were calculated. Altmetric score and downloads were
- 25 meta-analysed.
- **Results**. Article placement order did not associate with author gender or geographical region
- but was associated with funding source and research design. In addition, articles about
- 28 rheumatoid arthritis were more likely to be ordered at the front of issues (P<0.001). Articles
- 29 about crystal arthritis, systemic lupus erythematosus, vasculitis, pain syndromes and pediatric
- rheumatic diseases were more likely to be ordered at the end of issues (all P<0.001).
- 31 Association of article placement order with disease category was observed only in journals
- with tables of contents grouped by disease. Articles ordered in the first three places had
- higher Altmetric and download rates, than articles in the last three places.
- **Conclusions.** Author gender and geographical region do not influence article placement order
- in serial rheumatology journals. However, bias for certain disease categories is reflected in
- article placement order. Editorial decisions about article placement order can influence the
- 37 prominence of diseases.

**Keywords:** publication, bias, rheumatology

TO REPORT ONLY

## 41 Strengths and limitations of the study

- This is the first study to assess the relationship of article placement order in serial medical journals with author gender, geographical region of affiliated institution, industry funding, research design or disease category.
- This content analysis included 6,787 articles from general rheumatology journals.
- This study also analysed the impact of article placement order on research prominence,
   including Altmetric scores and download rate.
  - This analysis did not explore other factors that may have contributed to article placement order such as the originality of the study findings or the presence of "star" authors.

## INTRODUCTION

The strong preference for items ordered first, and the important effect of list order on choice,				
is well-recognised in consumer-based research.[1-3] In online searches for health				
information, 97% of selected links were displayed in the first 10 results, while only 2% were				
from the second or following pages.[4] For online academic repositories, earlier listed articles				
were downloaded more frequently than later listed articles.[5] These primacy effects, which				
increase when lists are longer,[6] may occur because earlier items, or those at the top of				
tables of contents, are more visible and more likely to be seen and read.[5]				
In academic publishing, the ordering of articles within a journal issue also affects the				
prominence achieved by that research. Earlier listed articles received more citations over a 25				
year period in a single journal.[7] The impact of ordering was also evident in an analysis of				
emails sent to subscribers disseminating recent research papers listed in random order; with				
the first paper having a 33% increase in views, 29% increase in downloads and 27% increase				
in citations, regardless of research quality.[8]				
A number of systemic biases have been reported in academic publishing. These include				
preferential lead and senior authorship of men,[9, 10] higher acceptance rates for articles				
from the US and Europe,[9, 11] preferential publication of industry-funded research,[12] and				
disease privileging, wherein particular diseases receive preferential research funding and				
publication.[13-15] It is unknown whether these systemic biases are reflected in article				
placement order within medical journals. We analysed serial rheumatology journals for				
relationships between article placement order and gender of the lead and senior authors,				
geographical region of the affiliated institution, industry sponsorship, and disease category.				

#### **METHODS**

## Patient and public involvement

77 There was no patient or public involvement in the design, or conduct, or reporting, of this

78 research.

#### Identification of journals and articles for inclusion

This was a cross-sectional content analysis of original articles published in general rheumatology journals. Journals were included if they produced regular issues, reported original research and had 2016 Thomas Reuters Impact Factors of > 3.0. Journals were excluded if they published review articles only, were disease-specific (e.g. *Lupus*, *Osteoarthritis and Cartilage*) or produced no issues. The following seven general rheumatology journals met the above criteria and were included: *Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Arthritis Care & Research, Seminars in Arthritis and Rheumatism, Rheumatology, Journal of Rheumatology, and Joint Bone Spine. Characteristics of the included journals are shown in Supplementary Table 1.* 

June 2018 were included in the analysis. To be included, articles could be full or concise reports, and report on original basic science or clinical research, including systematic reviews and meta-analyses. Articles were excluded if they were from a disease-specific thematic issue or supplement, were narrative reviews, recommendations, guidelines, letters, or meeting reports.

#### **Data extraction**

Data extraction was undertaken between June and December 2018. The following information was extracted for each included article; order number of article in the issue, gender of lead (first) author; gender of senior (final) author; geographical region of affiliated institution (for the first author); industry funding category (industry-funded and initiated, industry-funded and investigator-initiated, not industry-funded); research design (basic science, other clinical, randomised controlled trial, systematic literature/meta-analysis); and, if available, the Altmetric score and number of downloads. The number of citations was not assessed because of the short time period between publication and data extraction. If author gender could not be determined by first name or by an internet search of the author's affiliated institution profile page, then the author's first name was entered into https://api.genderize.io/?name= which returns the gender and probability of certainty. Probabilities < 0.5 were labelled as "unknown" and not included in the gender-related analysis. If articles were authored by a single author, then this author's gender was entered under first author. Funding was assessed by review of funding statements, disclosures and author affiliations. Industry-funded studies were categorized as industry-funded and industryinitiated, or industry-funded and investigator-initiated, based on these statements. Studies with no evidence of industry funding were categorized as not industry-funded. Articles were coded according to the following 13 disease categories: ankylosing spondylitis and other spondyloarthropathy, crystal arthritis, osteoarthritis, miscellaneous rheumatic disease, pediatric rheumatology, pain syndromes, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis/scleroderma, other connective tissue disorders, vasculitis, and not disease-specific. The title of each article was used to determine the disease category. If there was uncertainty about the disease category from the title, then the abstract and/or full paper were reviewed.

To ensure standardisation in data extraction, two authors (SS, ND) independently reviewed eligible papers from ten randomly selected issues. A total of 208 articles were reviewed, with kappas of 1.00 for author gender, geographical region, and industry funding category, while disease category had a kappa of 0.84 (86.1% agreement (95% confidence interval (CI) 81.0%, 90.5%)). All disease category disagreements were discussed to reach a consensus and a set of rules for categorising was established. The exercise was then repeated in which the two authors reviewed disease categories in a further five randomly selected issues totalling 85 articles, with a kappa of 0.99 (98.8% agreement (95% CI 94.3%, 99.9%)) for disease category. A single reviewer (SS) then independently extracted the data.

## **Data analysis**

The primary analyses assessed the relationships between article placement order and: gender of first authors, gender of last authors, geographical region (Europe, North America, Other), industry funding categories (industry-funded and initiated, industry-funded and investigator-initiated, not industry-funded), research design (basic science, other clinical research, randomised controlled trial, systematic literature review/meta-analysis) and disease categories. In order to identify whether these factors were associated with article placement order within journal issues, each article within each issue was assigned a standard article placement index (SAPI), which was defined as the order of the article in the issue/total number of articles in the issue. For example, the first article in an issue of 21 articles was given an SAPI of 1/21 = 0.0476 and the last article 21/21 = 1. This metric allowed standardisation of article placement order within issues with the expectation that the number of articles within each issue would vary widely across different journals. For example, the SAPI could scale between article placement in a journal issue of five articles and one with 50

articles. Therefore, this metric addressed the large variation in the number of articles between different journal issues and overcame the potential issue of skewed average article placement order data resulting from issues with large numbers of articles. The SAPI as a placement metric enabled the examination of article placement order without an assumption that the mean (or median) article placement order was different. Cumulative distribution functions (CDF) of SAPIs were analysed to determine the associations between article placement order and author gender, geographical region, industry funding and disease category. A uniform distribution would be expected if there was no association with article placement order: deviations from the expected uniform distribution would support an association with article placement order. Due to the potential over-sensitivity of this test, [16] the effect sizes (D) were also computed with values ranging from 0 (no difference in distribution of SAPI between comparisons) to 1 (large difference in distribution of SAPI between comparisons) to provide further description of the deviations between the observed distributions. To determine whether the distribution of SAPIs for variable was different from a uniform distribution CDF (expected distribution if no bias reflected in article placement order), the area under the curve (AUC) of the observed CDF and uniform distribution CDF were each calculated using a trapezoidal method and the difference between these estimated for each of the variable categories. Mean differences between the observed CDF and the uniform distribution CDF AUCs were computed from bootstrapped samples (500 replicates, sampled with replacement) and 95% confidence intervals estimated as the 2.5th and 97.5th percentile of the bootstrap distribution. P-values were calculated for each category from these confidence intervals using the method of Altman and Bland.[17] This analysis method allowed for an assumption-free comparison of the observed and expected distributions of SAPIs.[18] CDFbased comparisons are estimates and do not systematically increase or decrease with sample size. The estimated CDF, like an estimated mean, is unbiased at any sample size. The

estimation of the CDF (like estimation of a mean) assumed only that each variable examined provided some incremental information; that is, that collinearity was not close to perfect.[19] Unlike the comparison of a central tendency statistic (i.e. mean or median order placement), comparing these distributions allowed testing of any early and late article placement (bimodal) clustering (primacy and recency) as well as a uniform distribution of placement. CDF plots of SAPIs also provided a visually clear representation of article placement order and potential differences between groups.

A secondary analysis was undertaken to further explore article placement order, in which mid-P exact P-values were computed to compare the proportion of articles appearing in at least one of the first three places of an issue compared to at least one of the last three places of an issue for genders of first and last authors, geographical region, industry funding category, and each disease category. Odds ratios (OR) and their 95% CIs were also computed for articles in the first three places vs. last three places of an issue.

As some journals presented their content grouped by disease category, additional analyses were undertaken to determine whether article placement order of disease categories was different between journals which presented content grouped by disease category vs. journals without disease category content grouping. This was tested statistically using CDF plots of SAPI distributions, two-sample Kolmogorov Smirnov Z tests and effect sizes (KS D) as described above.

To further explore factors associated with article placement order, a supplementary *post hoc* analysis was undertaken to compare the median SAPIs between genders, geographical regions, industry funding categories and disease categories using Mann-Whitney U or Kruskal Wallis tests, as appropriate. Mann-Whitney U tests were also undertaken to determine whether article placement order for articles about rheumatoid arthritis differed

from other disease categories. Cohen's $d$ were computed for each comparison as measures of
effect size with scores of 0.2 considered small, 0.5 considered median and 0.8 considered
large [20].
Finally, to determine the impact of article placement order on Altmetric scores and article
download rates (as available), meta-analyses were used to determine differences in the means
for each variable between the first and last three articles in journal issues. Altmetric scores
were provided by Arthritis & Rheumatology, Annals of the Rheumatic Diseases,
Rheumatology and Arthritis Care & Research. Annals of the Rheumatic Diseases,
Rheumatology and The Journal of Rheumatology had article download data available, but for
the latter two journals, the data were available in only the 6 months prior to data extraction.
Therefore, analyses of article downloads were undertaken for Annals of the Rheumatic
Diseases only. For Altmetric scores, which generally do not change over time, mean scores
were calculated by total Altmetric scores/total number of articles. For downloads, which are
time dependent, rates were calculated by total number of downloads/total article-years from
time of publication to time of data extraction. These analyses were undertaken within disease
categories, adjusted by journal, as appropriate, and weighted using the inverse-variance
method. Random effects models were used.
All analyses were performed in SPSS (v25 IBM Corp) and SAS v9.4 (SAS Institute Inc,
Cary, NC). All tests were two-tailed and false discovery rate (FDR)-adjusted <i>P</i> values [21]
were computed for all analyses with an alpha level of $< 0.05$ considered significant.

#### **RESULTS**

#### **Characteristics of included articles**

First authors were male in 3250 (47.9%) articles, female in 3517 (51.8%) articles and unknown in 20 (0.3%) articles. Last authors were male in 4412 (65.0%) articles, female in 2359 (34.8%) articles and unknown/not applicable in 16 (0.2%) articles. The geographical region was Europe in 3486 (51.4%) articles, North America in 2177 (32.1%) articles, and Other in 1124 (16.6%) articles. 596 (8.8%) articles were industry-funded and initiated, 640 (9.4%) were industry-funded and investigator-initiated, and 5551 (81.8%) were not industryfunded. Of the included papers, 1,395 (20.6%) reported basic research, 4466 (65.8%) were categorised as other clinical research studies, 488 (7.2%) were randomised controlled trials and 438 (6.5%) were systematic literature reviews or meta-analyses. Disease categories were rheumatoid arthritis (n = 1946, 28.7%), osteoarthritis (n = 773, 11.4%), systemic lupus erythematosus (n = 642, 9.5%), ankylosing spondylitis (n = 496, 7.3%), pediatric rheumatology (n = 443, 6.5%), systemic sclerosis (n = 433, 6.4%), not disease-specific (n = 422, 6.2%), vasculitis (n = 362, 5.3%), other connective tissue disease (n = 339, 5.0%), miscellaneous (n = 277, 4.1%), crystal arthritis (n = 269, 4.0%), psoriatic arthritis (n = 242, 3.6%), and pain syndromes (n = 143, 2.1%). The specific diseases which were categorised under crystal arthritis, other connective tissue disease, and miscellaneous are shown in **Supplementary Table 2.** 

## Distribution of article placement within issues

Inspection of the cumulative distribution function plots showed no association of article placement order with author gender or geographical region. However, differences in article placement order were observed for funding source, research design and disease category

(Figure 1, Supplementary Table 3). Industry-funded and initiated studies and industryfunded and investigator-initiated studies were more likely to be placed towards the front of journal issues. Similarly, randomised controlled trials were placed towards the front of issues, while basic science research articles were placed towards the back of issues. Figure 2 and **Table 1** display the differences in article placement order for disease category. Articles about rheumatoid arthritis were more likely to be placed towards the front of issues. The placement of articles about ankylosing spondylitis, osteoarthritis and psoriatic arthritis conformed to a uniform distribution. Articles about systemic lupus erythematosus, other connective tissue diseases, crystal arthritis, systemic sclerosis, vasculitis, pediatric rheumatology and pain syndromes were more likely to be placed towards the back of issues. 

32 254

Table 1. Difference in distribution of standard article placement indices (SAPI) from a uniform distribution for each disease category
--

	N (%)	SAPI, mean	Difference in AUC between	Effect size (KS	
		(SD)	distribution	e S	$\mathbf{D})^{\mathbf{b}}$
			Mean (95% confidence	FDR adjusted P	
			interval) <sup>a</sup>	 D	
Ankylosing spondylitis	496 (7.3%)	0.51 (0.24)	+0.00 (-0.02, +0.01)	0.948	0.10
Crystal arthritis	269 (4.0%)	0.63 (0.28)	-0.13 (-0.14, -0.11)	< 0.0 1	0.21
Miscellaneous	277 (4.1%)	0.68(0.29)	-0.18 (-0.20, -0.15)	<0.0 <b>6</b> 1	0.30
Not disease-specific	422 (6.2%)	0.61 (0.30)	-0.09 (-0.10, -0.07)	<0.0 1	0.15
Osteoarthritis	773 (11.4%)	0.49 (0.24)	+0.00 (-0.01, +0.02)	0.88₹	0.14
Other connective tissue diseases	339 (5.0%)	0.62 (0.25)	-0.11 (-0.13, -0.09)	<0.001	0.20
Pediatric rheumatology	443 (6.5%)	0.69 (0.28)	-0.19 (-0.23, -0.18)	<0.001	0.29
Pain syndromes	143 (2.1%)	0.69 (0.27)	-0.18 (-0.26, -0.15)	<0.01	0.30
Psoriatic arthritis	242 (3.6%)	0.53 (0.24)	-0.01 (-0.04, 0.02)	$0.55^{\circ}$	0.10
Rheumatoid arthritis	1946 (28.7%)	0.36 (0.28)	+0.14 (+0.14, +0.16)	<0.091	0.30
Systemic lupus erythematosus	642 (9.5%)	0.58 (0.21)	-0.07 (-0.09, -0.05)	< 0.0 0	0.18
Systemic sclerosis	433 (6.4%)	0.64 (0.24)	-0.14 (-0.15, -0.12)	<0.001	0.23
Vasculitis	362 (5.3%)	0.65 (0.24)	-0.15 (-0.18, -0.12)	<0.091	0.27

AUC = area under the curve; CDF = cumulative density function; SAPI = standard articles placement index. aPositive differences indicate deviations from a uniform distribution above the uniform distribution function (i.e. article placement towards the front of an issue), while negative differences indicate deviations from a uniform distribution below the uniform distribution function (i.e. article placement towards the back of an issue). From one-sample Kolmogorov-Smirnov Z test.

## Articles in the first and last three places of an issue

There were no significant differences in the proportion of articles in the first vs. last three places of an issue for author gender, geographical regions, or industry funding category (Supplementary Table 4). However, consistent with the cumulative distribution function analysis, differences for disease category were observed (Figure 3, Supplementary Table 4). There was a significantly greater proportion of articles in the first three compared to the last three places of an issue for rheumatoid arthritis (35.6% vs. 8.7% P < 0.001) with an OR (95% CI) of 5.77 (4.80, 6.92). There was a similar proportion of articles in the first three and last three places of an issue for ankylosing spondylitis, osteoarthritis, or psoriatic arthritis. There was a significantly lower proportion of articles in the first three compared to the last three places of an issue for crystal arthritis (10.8% vs. 26.8%), other connective tissue diseases (6.8% vs., 16.5%), pediatric rheumatology (8.4% vs. 38.8%), pain syndromes (8.4% vs. 37.1%), systemic lupus erythematosus (4.7% vs. 9.7%), systemic sclerosis (4.4% vs. 18.2%) and vasculitis (6.4% vs. 18.0%) (all P < 0.001). Differences in the proportion of articles in the first vs. last three places of an issue were also observed for research type, with a significantly higher proportion of articles in the first three compared to the last three places of an issue for other clinical research (17.0% vs. 13.6%), randomised controlled trials (26.4%) vs. 10.9%), and systematic literature reviews/meta analyses (24.2% vs. 16.7%) (all P <0.003) and a significantly lower proportion of articles in the first three compared to last three for basic science research (7.6% vs. 26.2% P < 0.001) (Supplementary Table 4).

## Journals with and without content grouped by disease category

Arthritis & Rheumatology, Seminars in Arthritis and Rheumatism, Arthritis Care & Research and The Journal of Rheumatology grouped issue content by disease category with disease-

specific tables of contents sections, while *Annals of the Rheumatic Diseases*, *Rheumatology*, and *Joint Bone Spine* did not group issue content by disease category (**Supplementary Table 1**). Journals with content grouped by disease showed an association between article placement order and disease category, whereas this was less evident for journals without content grouped by disease (**Figure 4**). Comparisons between journals with and without content grouped by disease category demonstrated a significant difference in the SAPI distributions for every disease category, with articles on rheumatoid arthritis placed towards the front of issues, and articles on crystal arthritis, pain syndromes, pediatric rheumatology, systemic sclerosis and vasculitis placed towards the end of issues, in journals with content grouped by disease category (**Supplementary Table 5**).

## **Comparison of median Standardised Article Placement Indices (SAPIs)**

*Post hoc* analyses of the differences in median SAPIs between genders, geographical regions, industry funding categories and disease categories are shown in **Supplementary Table 6 and Supplementary Figure 1**. Significant differences in article placement order were observed between disease categories, with all categories demonstrating greater median SAPIs (indicative of placement towards the back of journal issues) compared to rheumatoid arthritis (all P < 0.001).

## The impact of article placement order on Altmetric scores and downloads

The impact of article placement order was evident in the meta-analysis results, which showed a higher Altmetric score (adjusted for journal) for articles published in the first three places of an issue compared with the last three, (mean difference in Altmetric score of 5.11, 95% CI 1.50, 8.71, Z = 2.78, P = 0.005) (**Figure 5**). The difference in Altmetric scores varied across

different disease categories ( $I^2$  76%; P < 0.001), with the largest difference between positioning in the first three places and positioning in the last three places being observed for articles about rheumatoid arthritis and psoriatic arthritis.

Similarly, meta-analysis showed that articles published in the first three places of an issue had a higher download rate compared to articles in the last three places of an issue (pooled rate difference (95% CI) 442.1 (293.0, 591.2) downloads/article year, Z = 5.81, P < 0.001) (**Figure 5**). The difference in download rate between the first and last three articles was similar across different disease categories ( $I^2$  24%; P = 0.21).

#### **DISCUSSION**

In this analysis of serial rheumatology journals, no relationship between article placement order and author gender or geographical region was observed. However, differences for funding source, research design, and disease category were apparent. There was more frequent positioning of industry-funded studies and randomised controlled trials towards the front of journal issues. Articles about rheumatoid arthritis were also more frequently positioned towards the front of journal issues, while articles about crystal arthritis, other connective tissue diseases, pediatric rheumatology, pain syndromes, systemic lupus erythematosus, systemic sclerosis and vasculitis towards the back of issues. Analyses of Altmetric scores and download rates suggested that article placement order influences research prominence, with earlier placed articles receiving more attention.

Medical journals are central to evidence-based practice and represent a key source of new knowledge for medical professionals.[22, 23] Unbiased publication practices are important in allowing a variety of perspectives and emphases to expand the scope of research and clinical practice. Although bias has been previously reported in academic journals based on

authorship ordering of genders, [9, 10] representation of geographical regions, [9, 11] and acceptance and time to publication based on industry sponsorship,[12] our analysis showed that of these factors only industry funding was associated with article placement order within serial rheumatology journals. This finding may reflect the placement of clinical trials towards the front of issues which likely made up the majority of industry-funded studies. Articles about rheumatoid arthritis were preferentially placed towards the front of rheumatology journals, while other conditions, particularly pain syndromes, crystal arthritis, pediatric syndromes, and connective tissue diseases, were ordered towards the back. Rheumatoid arthritis was the disease category with the greatest number of articles, therefore giving it the greatest opportunity to be listed first, but our analyses accounted for the variation in article numbers between disease categories. Although rheumatoid arthritis is a very important rheumatic disease, [24] general rheumatology practice involves the diagnosis and treatment of a wide range of diseases. [25, 26] General rheumatology journals should ideally reflect that diversity of clinical practice. A similar distribution of articles on each disease category would therefore be expected if there was no bias for disease category. The reason for the observed differences in article placement for disease category is unclear. Disease privileging in other fields of medical research has been reported, with some prevalent diseases with high global impact being under-funded and under-researched.[13-15] Crystal arthritis, osteoarthritis and pain syndromes are common; for example, prevalence estimates for US adults for gout are 3.9%,[27] for osteoarthritis are 13.4%,[28] and for low back pain are 26.4%.[29] However, these conditions may be viewed by rheumatologists and journal editors as less important or less severe.[30, 31] Our analysis of article placement order, which did not reflect prioritising of diseases based on epidemiology or severity, emphasises the disconnect between the prevalence of disease and health research. These perceptions of some rheumatic diseases have the potential to impact attitudes in clinical practice and contribute to

lower quality of care.[31, 32] Rheumatic diseases such as vasculitis, pediatric rheumatic disease, and scleroderma are less common, but can lead to major morbidity and reduced quality of life. Improving the impact and accessibility of research published on 'lower priority' or less common rheumatic diseases may have an important impact on clinicians' understanding about and attitudes towards these conditions in clinical practice. Differences in article placement order for disease category was particularly evident in journals with disease-specific tables of contents sections within issues, rather than journals that did not group issue content by disease category. It has been suggested that grouping article content by disease category may improve the reader experience.[33] However, such decisions have the potential to further reduce readers' exposure to diseases that are already under-studied or less well understood. Editorial decisions to remove grouping by disease category, or to cycle the order of disease category groups for each issue may be a simple solution to overcome bias for disease category reflected in article placement order. In our analysis, articles appearing in the first three places of an issue had higher Altmetric scores and download rates compared to articles appearing in the last three places of an issue. This finding may be attributed in part to the higher number of clinical trials published towards the front of issues, which generally have a greater impact [34], and is also consistent with prior studies which demonstrate the influence of the primacy effect on research prominence. [6-8] Collectively, these findings indicate that articles placed at the front of journal issues receive greater prominence. The prominence and impact of research published in journals has an important role in not only providing information to improve knowledge and treatment, but also in financing further research[35] and obtaining academic promotion.[36] The current analysis has some limitations. Firstly, Altmetric and download data were not available from all journals included in the analysis, and it is unclear whether similar

of the short time period between article publication and data extraction which would not have reflected true citation rates, which increase over time. Finally, this analysis did not explore other factors that may have contributed to article placement order such as quality, impact, or originality of the study, or the presence of prolific or "star" authors.[37] Further research may also focus on identifying factors influencing editorial decisions about the placement order of articles about different diseases. For example, we did observe that basic science articles were placed towards the back of an issue, suggesting that editors prioritise clinical research over laboratory-based research. A strength of this paper is the use of multiple methods of analysis to explore the relationship between disease category and article placement order, including an analysis of the distribution of article placement, an analysis of the difference in proportion of articles appearing in the first and last three places of an issue, and an analysis of the comparison of median article placement order between disease categories. Collectively, these results provide robust and detailed evidence that bias for industry funded studies, clinical trials and for certain disease categories is reflected in article placement order.

In conclusion, author gender and geographical region do not influence article placement order in serial rheumatology journals. However, bias for certain disease categories is reflected in article placement order. Article placement order may have an impact on research prominence, including Altmetric scores and download rate. Editorial choices about the serial position of articles within journals can influence prioritisation of certain diseases.

Acknowl	edgements
---------	-----------

None.

## **Competing interests**

ND has received consulting fees, speaker fees or grants from AstraZeneca, Horizon, Amgen, Arthrosi, Dyve Biosciences, Hengrui, Abbvie, Pfizer, and Janssen, outside the submitted work. ND and SS work primarily in the field of gout research (a condition that was analysed in this research project). GG and AG declare no competing interests.

#### **Funding**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

#### **Author contributions**

SS contributed towards acquisition, analysis and interpretation of the data. GG contributed towards design of the study and analysis and interpretation of the data. AG contributed towards design of the study and interpretation of the data. ND contributed towards design of the study, and acquisition and interpretation of the data. All authors were involved in drafting of the work or revising it critically for important intellectual content. All authors approved the final version to be published and agree to be accountable for all aspects of the work.

**Data statement** 

availab All extracted data used in the analyses are available upon reasonable request from the 

corresponding author. 

RF	FE	RE	N(	CES
----	----	----	----	-----

- [1] Chen E, Simonovits G, Krosnick JA, Pasek J. The impact of candidate name order on election outcomes in North Dakota. *Elect Stud* 2014;35:115–22.
- 428 [2] Becker SL. Why an order effect? *Public Opin Q* 1954;18:271–8.
- 429 [3] Mantonakis A, Rodero P, Lesschaeve I, Hastie R. Order in choice: effects of serial position on preferences. *Psychol Sci* 2009;20:1309–12.
- [4] Eysenbach G, Köhler C. How do consumers search for and appraise health information on the world wide web? Qualitative study using focus groups, usability tests, and in-depth interviews. *BMJ* 2002;324:573–7.
- [5] Haque A-u, Ginsparg P. Positional effects on citation and readership in arXiv. *J Assoc Inf* Sci Technol 2009;60:2203–18.
- 436 [6] Novarese M, Wilson CM. Being in the right place: a natural field experiment on list 437 position and consumer choice. MPRA Paper 48074, University Library of Munich, 438 Germany; 2013.
- 439 [7] Jonah B. Does presentation order impact choice after delay? *Top Cogn Sci* 2016;8:670–440 84.
- [8] Feenberg D GI, Gaule P, Gruber J. It's Good to be First: Order Bias in Reading and Citing
  NBER Working Papers. *Rev Econ Stat* 2015;99:32–9.
- [9] Filardo G, da Graca B, Sass DM, Pollock BD, Smith EB, Martinez MA-M. Trends and
   comparison of female first authorship in high impact medical journals: observational
   study (1994-2014). *BMJ* 2016;352:i847.
- West JD, Jacquet J, King MM, Correll SJ, Bergstrom CT. The role of gender in scholarly authorship. *PLoS One* 2013;8:e66212.

- Edwards HA, Schroeder J, Dugdale HL. Gender differences in authorships are not associated with publication bias in an evolutionary journal. *PLoS One* 2018;13:e0201725.
- 450 [12] Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship
- and research outcome and quality: systematic review. *BMJ* 2003;326:1167–70.
- 452 [13] Yegros A, Tijssen R, Abad-García M-F, Ràfols I. Drug research priorities at odds
- with global disease toll [Blog]. Nature Index 2018. Accessed on 6/8/2019 from:
- https://www.natureindex.com/news-blog/drug-research-priorities-at-odds-with-global-
- disease-toll
- Lobner K, Lanzkron S, MHS, Haywood C. NIH and National Foundation
- expenditures for sickle cell disease and cystic fibrosis are associated with Pubmed
- publications and FDA approvals. *Blood* 2013;122:1739.
- 459 [15] Catalá-López F, García-Altés A, Álvarez-Martín E, Gènova-Maleras R, Morant-
- Ginestar C. Does the development of new medicinal products in the European Union
- address global and regional health concerns? *Popul Health Metr* 2010;8:34-43.
- 462 [16] Micceri T. The unicorn, the normal curve and other improbable creatures. *Psychol*
- *Bull* 1989;105:156-66.
- 464 [17] Altman DG, Bland JM. How to obtain the P value from a confidence interval. BMJ
- 465 2011;343:d2304.
- 466 [18] Bolland MJ, Gamble GD, Avenell A, Grey A, Lumley T. Baseline P value
- distributions in randomized trials were uniform for continuous but not categorical
- 468 variables. *J Clin Epidemiol* 2019;112:67-76.
- 469 [19] Storey JD, Tibshirani R, Statistical significance for genomewide studies. *Proc of the*
- *Nat Acady Sci U S A* 2003;100:9440-5.
- 471 [20] Cohen J. Statistical power analysis for the behavioural sciences (2nd ed.). 1988.
- 472 Hillsdale, NJ: Erlbaum.

- 473 [21] Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
  474 powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol* 1995;57:289–
  475 300.
- Laine C, Weinberg D. How can physicians keep up-to-date? *Annu Rev Med*1999;50:99–110.
- Sackett DL, Rosenberg WM. The need for evidence-based medicine. *JRSM* 1995;88:620–4.
- 480 [24] Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates 481 from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73:1316–22.
- 182 [25] Ng X, Low AHL, Chew L-C, et al. Disease patterns of rheumatology outpatients seen in a tertiary hospital serving a multi-ethnic, urban Asian population in Singapore. *Int J*184 *Rheum Dis* 2013;16:273–8.
- Miedema HS, van der Linden SM, Rasker JJ, Valkenburg HA. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. *Rheumatol* 1998;37:555–61.
- Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general
   population: The National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011;63:3136-41.
- [28] Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative
   methods for defining osteoarthritis and the impact on estimating prevalence in a US
   population-based survey. *Arthritis Care Res* 2016;68:574-80.
- Deyo RA, Mirza SK, Martin BI, Back pain prevalence and visit rates: estimates from
   U.S. national surveys 2002. *Spine* 2006;31:2724-7.
- [30] Birrell F, Arden NK, Conaghan PG, Cooper C, Dieppe P, Doherty M. Is it time for
   more rheumatologists to embrace osteoarthritis? *Rheumatol* 2005;44:829-30.

498	[31]	Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269–
499	70	

- Chua JR, Jamal S, Riad M, et al. Disease burden in osteoarthritis is similar to that of rheumatoid arthritis at initial rheumatology visit and significantly greater six months later. *Arthritis Rheumatol* 2019; doi: 10.1002/art.40869
- 503 [33] Smolen JS. Greetings from the editor 2019. Ann Rheum Dis 2019;78:1–2.

research proposals? PLoS One 2013;8:e68258.

- 504 [34] Patsopoulos NA, Analatos AA, Ioannidis JPA. Relative Citation Impact of Various Study Designs in the Health Sciences. *JAMA* 2005; 293:2362-6.
- [35] Cabezas-Clavijo Á, Robinson-García N, Escabias M, Jiménez-Contreras E.
   Reviewers' ratings and bibliometric indicators: hand in hand when assessing over
- [36] Holden G, Rosenberg G, Barker K. Bibliometrics: a potential decision making aid in
   hiring, reappointment, tenure and promotion decisions. *Soc Work Health Care* 2005;41:67–92.
- 512 [37] Tomkins A, Zhang M, Heavlin WD. Reviewer bias in single- versus double-blind 513 peer review. *Proc Natl Acad Sci U S A* 2017;114:12708-1

#### Figure legends


**Figure 1.** Cumulative distribution function plots of standardised article placement indices (SAPI) for first author gender (**A.**), senior author gender (**B.**), industry funding (**C.**), and first author's geographic region of affiliated institution (**D.**), and research design (**E.**). Left deviated distributions suggest prioritisation towards the front of journal issues.


**Figure 2.** Cumulative distribution function plots of standardised article placement indices (SAPI) for each disease category. Left deviated distributions suggest prioritisation towards the front of journal issues.


**Figure 3.** Percentage of articles (per disease category) published in first three and last three places of an issue (*P*-values indicate difference between proportions of articles in first and last three places of an issue).


**Figure 4.** Cumulative distribution function plots of standardised article placement indices (SAPI) for each disease category for journals with (**A.**) and without (**B.**) contents grouped by disease. Left deviated distributions suggest prioritization towards the front of journal issues.


**Figure 5.** Forest plots showing the mean differences for each disease category for Altmetric scores (**A.**) and download rates (**B.**) between articles published in the first vs. last three places of an issue. Positive differences indicate a higher Altmetric score/download rate for articles published in one of the first three places of an issue. Differences in Altmetric scores are adjusted for journal. Download data was available from one journal. CTD: connective tissue disease.














For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# A. Journals with issue content grouped by disease



## B. Journals without issue content grouped by disease





### BMJ Open A. Differences in Altmetric scores between articles in first and last three places of an issue

	First thre	ee	Last three		Score			Mean difference, random effe		
	Mean score	N	Mean score	N	Weight	difference	95% CI	analysis, 95% CI		
Ankylosing spondylitis	14.19	32	6.10	31	7.44%	8.09	(-0.70, 16.88)			
Crystal arthritis	9.10	21	25.23	39	2.90%	-16.14	(-34.85, 2.58)	<del></del>		
Miscellaneous	10.95	20	4.18	50	9.93%	6.77	(0.99, 12.55)			
Not disease-specific	28.47	36	7.73	66	2.40%	20.74	(-0.33, 41.82)	June		
Osteoarthritis	18.47	47	20.26	47	4.20%	-1.79	(-16.35, 12.77)	<del></del>		
Other CTDs	6.421	19	3.57	47	11.91%	2.85	(-0.58, 6.27)	2020.		
Pediatric rheumatology	7.14	29	5.57	86	11.63%	1.57	(-2.21, 5.35)	——————————————————————————————————————		
Pain syndromes	48.36	11	26.10	29	0.61%	22.26	(-22.78, 67.30)	<del> </del>		
Psoriatic arthritis	13.00	17	3.00	17	8.38%	13.06	(5.46, 20.65)	<b>-■</b> - Š		
Rheumatoid arthritis	24.16	434	4.03	156	9.01%	20.13	(13.29, 26.97)	-■- 등		
stemic lupus erythematosus	12.59	27	7.69	58	7.69%	4.90	(-3.55, 13.36)	<del> =</del> &		
Systemic sclerosis	3.88	17	2.81	69	12.50%	1.07	(-1.49, 3.63)	<b>⊭</b> ed		
Vasculitis	2.68	22	4.41	37	11.42%	-1.72	(-5.77, 2.33)	Downloaded from		
Total		732		732	100.0	5.11	(1.50, 8.71)	-40 -20 0 20 40 60 by Last three First three		

B. Differences in download rates between articles in first and last three places of an issue

	First thr	ee	Last thre	ee		Rate		Mean difference, random
_	Mean score	N	Mean score	N	Weight	difference	95% CI	effects analysis, 95% Cl
Ankylosing spondylitis	842.8	17	344.9	10	10.9%	497.9	(115.6, 880.3)	20
Crystal arthritis	726.3	9	198.1	5	8.88%	528.3	(89.2, 967.3)	2024
Miscellaneous	1073.5	7	385.3	12	5.18%	688.1	(78.7, 1297.6)	<del></del> by
Not disease-specific	1430.0	15	336.0	15	1.95%	1093.9	(54.7, 2133.1)	
Osteoarthritis	465.5	13	457.2	22	12.04%	8.2	(-347.9, 364.4)	_ <del>+</del> _
Other CTDs	785.3	5	389.1	14	8.40%	396.2	(-58.7, 851.1)	guest.
Pediatric rheumatology	758.2	6	626.0	4	3.07%	132.2	(-683.7, 948.1)	
Pain syndromes	1110.5	3	346.4	1	0.00%	Excluded		Prot
Psoriatic arthritis	1408.0	14	491.8	3	1.20%	916.2	(-426.3, 2258.7)	
Rheumatoid arthritis	952.2	76	358.8	54	24.23%	593.4	(409.2, 777.6)	cted by
ystemic lupus erythematosus	880.0	11	538.7	12	10.36%	341.3	(-54.6, 737.2)	<del>  ■                                   </del>
Systemic sclerosis	480.6	5	286.8	25	9.19%	193.9	(-235.4, 623.1)	<del> ■</del> ×
Vasculitis	961.3	3	142.0	6	4.59%	819.3	(165.95, 1472.7)	— 🗝 👸
Total		183		184	100.0	442.1	(293.0, 591.2)	copyright.

Heterogeneity: Tau² = 15400; Chi² = 14.4; l² = 23.7% (P = 0.211)

Frespre Verine (P = 5 to project of the control of the contr

First three

Page 34 of 40

### SUPPLEMENTARY MATERIAL

#### **Supplementary Table 1. Journal characteristics**

						202		Number of included
	Publisher	Country of publication	2016 Impact Factor	Relevant affiliated society	Issues per year	Contents Frouped by Lisease	Total number of articles included, n	articles per issue, mean (SD)
Annals of the Rheumatic Diseases	BMJ Publishing Group Ltd	United Kingdom	12.811	European League Against Rheumatism	12	nto ac	1374	13.2 (9.4)
Arthritis & Rheumatology	John Wiley & Sons	United States	6.918	American College of Rheumatology	12	od Oges ⇒†	1367	12.5 (7.6)
Rheumatology	Oxford University Press	United Kingdom	4.818	British Society for Rheumatology	12	fræm H	1158	10.2 (5.7)
Seminars in Arthritis and Rheumatism	Elsevier	United States	4.498	None	6	<b>≱</b> es <b>S</b>	403	7.3 (4.1)
Joint Bone Spine	Elsevier	United States	3.329	French Society of Rheumatology	6	<b>1</b> 000000000000000000000000000000000000	239	4.6 (2.6)
Arthritis Care & Research	John Wiley & Sons	United States	3.319	American College of Rheumatology, Association of Rheumatology Health Professionals	12	bes en.b	1098	9.6 (5.4)
The Journal of Rheumatology	Journal of Rheumatology Publishing Company Limited	Canada	3.150	Canadian Rheumatology Association	12	≩es C	1148	10.3 (6.1)

Supplementary Table 2. Number of articles within each disease category for crystal arthritis, miscellaneous and other connective tissue diseases

other connective tissue diseases	Frequency	Percent
Crystal arthritis (n = 269)	quency	
Gout	260	96.7
Calcium crystal diseases	9	3.3
Miscellaneous Disease (n = 277 articles)		
Regional musculoskeletal syndromes	48	17.3
Osteoporosis	22	7.9
IgG4-related disease	20	7.2
FMF	20	7.2
Polymyalgia rheumatica	19	6.9
	16	5.8
Still's disease	10	3.6
Septic arthritis	8	2.9
Fibrosis	8	2.9
Sarcoidosis	7	2.5
Chikungunya Virus	7	2.5
SAPHO syndrome	6	2.2
TRAPS	5	1.8
CAPS Still's disease Septic arthritis Fibrosis Sarcoidosis Chikungunya Virus SAPHO syndrome TRAPS Polychondritis Ehlers-Danlos Syndrome Lyme disease Alkaptonuria Hemophagocytic syndromes Vertebral fractures Uveitis Undifferentiated arthritis Tuberculosis Periodic fever syndrome Löfgren syndrome Erdheim-Chester disease	5	1.8
Ehlers-Danlos Syndrome	4	1.4
Lyme disease	4	1.4
Alkaptonuria	4	1.4
Hemophagocytic syndromes	3	1.1
Vertebral fractures	2	0.7
Uveitis	2	0.7
Undifferentiated arthritis	2	0.7
Tuberculosis	2	0.7
Periodic fever syndrome	2	0.7
Löfgren syndrome	2	0.7
Erdheim-Chester disease	2	0.7
Dupuytren's disease	2	0.7
ACPA-negative undifferentiated arthritis	1	0.4
Yellow fever	1	0.4
Whipple disease	1	0.4
Vertebral endplate lesions	1	0.4
Tumoral calcinosis	1	0.4
Tenosynovial giant cell tumor	1	0.4
Systemic autoinflammatory disease (SAID)	1	0.4
Schnitzler's syndrome	1	0.4
Ribbing disease	1	0.4
Receptor-associated periodic syndrome	1	0.4
Pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome	1	0.4
Pyogenic arthritis	1	0.4
Primary angiitis of the CNS	1	0.4
Preeclampsia	1	0.4
Pigmented villonodular synovitis	1	0.4
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA)	1	0.4
syndrome		

Paraneoplastic rheumatic syndrome	1	0.4
Palindromic rheumatism	1	0.4
Paget's disease	1	0.4
Osteonecrosis	1	0.4
Osteomyelitis	1	0.4
NOD2-associated autoinflammatory diseases	1	0.4
Muckle-wells syndrome	1	0.4
Mikulicz's disease	1	0.4
Mevalonate kinase deficiency	1	0.4
Medial meniscal tears	1	0.4
Macrophage activation syndrome	1	0.4
Leri's pleonosteosis	1	0.4
Kikuchi-Fujimoto disease	1	0.4
Joint hypermobility syndrome	1	0.4
Immune reconstitution inflammatory syndrome	1	0.4
Hereditary recurrent fever syndromes	1	0.4
Hereditary haemochromatosis	1	0.4
Hereditary haemochromatosis Haploinsufficiency of A20 Glomerulonephritis Gaucher disease Femoral fractures Fabry disease Ebola virus	1	0.4
Glomerulonephritis	1	0.4
Gaucher disease	1	0.4
Femoral fractures	1	0.4
Fabry disease	1	0.4
Ebola virus	1	0.4
Discitis	1	0.4
Chronic graft-versus-host disease	1	0.4
Blau syndrome	1	0.4
Biphosphate trochanteric fracture	1	0.4
Amyloidosis	1	0.4
Aicardi-Goutières syndrome	1	0.4
Other connective tissue disease (n = 339 articles)		
Sjogren's syndrome	174	51.3
Inflammatory myositis	115	33.9
Antiphospholipid syndrome	41	12.1
Mixed connective tissue disease	7	2.1
CTD-associated interstitial lung disease	1	0.3
Undifferentiated connective tissue disease	1	0.3

BMJ Open

Supplementary Table 3. Difference in distribution of standard article placement indices (SAPI) for each author gender, geographical region, industry finding cotogony and research design category and research design

	N (%)	SAPI, mean (SD)	Two-sample Kolgnogorov-Smirnov Z test		
	, ,	, , , ,	Effect size (KS D)	FDR-adjusted P	
First author gender			٦٠		
Female	3517 (52.0%)	0.53 (0.29)	0.02	0.19	
Male	3250 (48.0%)	0.52 (0.29)	0.03	0.19	
Last author gender			)20		
Female	2359 (34.8%)	0.52 (0.28)	0.04 D	0.017	
Male	4412 (65.2%)	0.53 (0.29)	0.04 o	0.017	
Geographical region			nlo		
Europe	3486 (51.4%)	0.53 (0.29)	(reference)	-	
North America	2177 (32.1%)	0.52 (0.29)		0.57	
Other	1124 (16.6%)	0.52 (0.29)	0.03 ਹੈਂ	0.93	
Industry funding	700		m +		
Industry funded and initiated	640 (9.4%)	0.42 (0.28)	0.19 ₹	< 0.001	
Industry funded and investigator initiated	596 (8.8%)	0.45 (0.29)	0.17	< 0.001	
Not industry funded	5551 (82.0%)	0.55 (0.29)	0.17 (reference)	-	
Research design			(reference)		
Basic science	1395 (20.6%)	0.64 (0.28)		=	
Other clinical research	4466 (65.8%)	0.51 (0.28)	0.22	< 0.001	
Randomised controlled trials	488 (7.2%)	0.41 (0.29)	0.34	< 0.001	
Systematic literature reviews/meta-analyses	438 (6.4%)	0.49 (0.29)	0.24	< 0.001	

SAPI = standard articles placement index. Lower SAPI scores equate to articles ordered at the front of issues, while higher SAPIqcores equate to articles ordered at the end of issues.

BMJ Open

BMJ Open

Supplementary Table 4. Number of articles appearing in at least one article in first and last three articles of an issue for author gender, geographical region of affiliated institution, industry funding category, and disease category funding category, and disease category

	Total articles	First thre		Last thr		Odds ratio	550 0	95% CI for OR	$P^{ m b}$
	ा जाता ता प्राप्तह	N	% of total	N	% of total	(OR) <sup>a</sup>	on	75 /0 CI 101 UK	1
irst author gender							17 Jur		
emale	3517	537	15.3%	586	16.7%	0.90	_	0.79, 1.02	0.17
Iale	3250	557	17.1%	509	15.7%	1.11	Ī	0.98, 1.27	0.17
ast author gender							ē		
emale	2359	393	16.7%	355	15.0%	1.13	20	0.97, 1.32	0.17
Male	4412	705	16.0%	737	16.7%	0.95	2020	0.85, 1.01	0.37
Geographical region						****			
Europe	3486	573	16.4%	556	16.0%	1.04	Ď	0.91, 1.18	0.68
North America	2177	362	16.6%	352	16.2%	1.03	ĕ	0.88, 1.21	0.68
Other	1124	163	14.5%	190	16.9%	0.83	Downlo	0.66, 1.05	0.35
ndustry funding	1124	103	14.570	170	10.7/0	0.03	ĕ	0.00, 1.03	0.55
ndustry-funding ndustry-funded and initiated	640	104	16.3%	109	17.0%	0.95	aded	0.70, 1.27	0.71
ndustry-funded and infrated	596	87	14.6%	109	18.6%	0.75	<u> </u>	0.70, 1.27	0.71
Not industry-funded and investigator-initiated	5551	907	14.6%	878	15.8%	1.04	from	0.55, 1.01	0.09
2	2221	907	10.3%	8/8	13.8%		_	0.94, 1.15	0.09
Research type	1205	100	7.60/	266	26.20/	0.22	Ħ.	0.10, 0.20	0.001
Basic science	1395	106	7.6%	366	26.2%	0.23	http://bmjo	0.18, 0.29	< 0.001
Other clinical research	4466	757	17.0%	606	13.6%	1.30	\$	1.16, 1.46	< 0.001
Randomised controlled trials	488	129	26.4%	53	10.9%	2.95	Ĭ	2.08, 4.18	< 0.001
ystematic literature reviews / meta-analyses	438	106	24.2%	73	16.7%	1.60	<u>ö</u> .	1.14, 2.23	0.003
Disease category							ре		
Ankylosing spondylitis	496	47	9.5%	40	8.1%	1.19	<u></u>	0.77, 1.86	0.51
Crystal arthritis <sup>c</sup>	269	29	10.8%	72	26.8%	0.33	pen.bmj.com/	0.21, 0.53	< 0.001
Miscellaneous	277	28	10.1%	103	37.2%	0.19	듯.	0.12, 0.30	< 0.001
Not disease-specific	422	52	12.3%	121	28.7%	0.35	8	0.24, 0.50	< 0.001
Osteoarthritis	773	81	10.5%	82	10.6%	0.99	ヹ	0.71, 1.37	0.934
Other connective tissue diseases	339	23	6.8%	56	16.5%	0.37	9n	0.22, 0.61	< 0.001
Pediatric rheumatology	443	37	8.4%	172	38.8%	0.14		0.10, 0.21	< 0.001
ain syndromes	143	12	8.4%	53	37.1%	0.16	April	0.08, 0.31	< 0.001
Psoriatic arthritis <sup>c</sup>	242	26	10.7%	23	9.5%	1.15		0.63, 2.07	0.71
Rheumatoid arthritis	1946	692	35.6%	170	8.7%	5.77	16	4.80, 6.92	< 0.001
systemic lupus erythematosus	642	30	4.7%	62	9.7%	0.46		0.29, 0.72	0.001
systemic rupus erythematosus	433	18	4.4%	79	18.2%	0.19	2024	0.11, 0.33	< 0.001
Vasculitis	362	23	6.4%	65	18.0%	0.19	24	0.11, 0.55	< 0.001
ascullus	302						_	riatic arthritis' came	

BMJ Open

BMJ Open

Supplementary Table 5. Difference in cumulative density function distribution of standard article placement indices (SAPI) between journals with and without contents grouped by disease for articles with related editorials and for each disease category. articles with related editorials and for each disease category

	Journals with co	Journals with contents not grouped by disease			ntents grouped	by disease	Two-sample Kolmogorov-Smirnov Z testb		
	N (%)	<b>SAPI</b> <sup>a</sup>		N (%)	SAPI <sup>a</sup>		Effect size (KS D)	FDR-adjusted P	
		Mean	SD		Mean	SD	7 J		
Ankylosing spondylitis	228 (8.2%)	0.49	0.28	268 (6.7%)	0.52	0.19	0.20	< 0.001	
Crystal arthritis	137 (4.9%)	0.49	0.28	132 (3.3%)	0.78	0.20	0.50	< 0.001	
Miscellaneous	152 (5.5%)	0.62	0.30	125 (3.1%)	0.76	0.26	0.29	< 0.001	
Not disease-specific	178 (6.4%)	0.53	0.30	244 (6.1%)	0.66	0.29	0.22	< 0.001	
Osteoarthritis	231 (8.3%)	0.55	0.27	542 (13.5%)	0.47	0.22	0.20	< 0.001	
Other connective tissue diseases	167 (6.0%)	0.49	0.29	172 (4.3%)	0.70	0.17	0.36 on d	< 0.001	
Pediatric rheumatology	121 (4.4%)	0.48	0.26	322 (8.0%)	0.77	0.25	0.50	< 0.001	
Pain syndromes	41 (1.5%)	0.54	0.35	102 (2.5%)	0.75	0.21	0.36 중	0.001	
Psoriatic arthritis	109 (3.9%)	0.48	0.27	133 (3.3%)	0.56	0.20	0.22	0.005	
Rheumatoid arthritis	881 (31.8%)	0.51	0.29	1065 (26.5%)	0.23	0.20	0.49	< 0.001	
Systemic lupus erythematosus	193 (7.0%)	0.56	0.28	449 (11.2%)	0.58	0.17	0.19	< 0.001	
Systemic sclerosis	182 (6.6%)	0.60	0.30	251 (6.3%)	0.68	0.18	0.26	< 0.001	
Vasculitis	151 (5.4%)	0.51	0.28	211 (5.3%)	0.75	0.14	0.50	< 0.001	

<sup>&</sup>quot;Lower SAPI scores equate to articles ordered at the front of issues, while higher SAPI scores equate to articles ordered at the end of issues. bTest of difference in distribution of SAPI between journals with and without contents grouped by disease sections.


BMJ Open

Supplementary Table 6. Comparison of median standardised article placement index (SAPI) between genders of first and last authors, geographical regions, industry funding categories and disease categories.

SAPI

	N of articles	SAPI <sup>a</sup>		Difference in median SAPI			
	N of articles	Median (IQR)	Min-max	Effect size (Colen's d)	FDR-adjusted P- value		
First author gender				17,			
Female	3517	0.53 (0.49)	0.02-1.00	0.04 June			
Male	3250	0.52 (0.51)	0.02-1.00		0.11		
Last author gender				2020.			
Female	2359	0.52 (0.49)	0.02-1.00				
Male	4412	0.23 (0.51)	0.02-1.00	0.05 Downloaded fro	0.07		
Geographical region				<u> </u>			
Europe	3486	0.53 (0.50)	0.02-1.00	oac			
North America	2177	0.51 (0.51)	0.02-1.00	0.02	0.26		
Other	1124	0.56 (0.51)	0.02-1.00	fr			
Industry funding				3			
Industry funded and initiated	640	0.36 (0.47)	0.02-1.00	h <sub>tt</sub>			
Industry funded and investigator initiated	596	0.42 (0.47)	0.02-1.00	0.30	< 0.001		
Not industry funded	5551	0.56 (0.49)	0.02-1.00	m http://bmjopen.bmj.com/	101001		
Research type				<u>Б</u> .			
Basic science	1395	0.71 (0.28)	0.03-1.00	<b>e</b> n.			
Other clinical research	4466	0.50 (0.47)	0.02-1.00	bп			
Randomised controlled trials	488	0.36 (0.46)	0.02-1.00	0.19	< 0.001		
Systematic literature reviews/meta-analyses	438	0.50 (0.51)	0.02-1.00	om om			
Disease category		<u></u>					
Ankylosing spondylitis	496	0.50 (0.35)	0.02-1.00	0.53 A Prii 0.59 0.68	< 0.001		
Crystal arthritis	269	0.70 (0.50)	0.05-1.00	0.59	< 0.001		
Miscellaneous	277	0.78 (0.45)	0.02-1.00	0.68	< 0.001		
Not disease-specific	422	0.63 (0.54)	0.03-1.00	0.64 م	< 0.001		
Osteoarthritis	773	0.45 (0.32)	0.05-1.00	0.58 0.66 22	< 0.001		
Other connective tissue diseases	339	0.67 (0.37)	0.02-1.00	0.66	< 0.001		
Pediatric rheumatology	443	0.79 (0.47)	0.05-1.00	0.86	< 0.001		
Pain syndromes	143	0.75 (0.37)	0.02-1.00	0.51	< 0.001		
Psoriatic arthritis	242	0.53 (0.33)	0.05-1.00	0.86 by 0.51 gu	< 0.001		
Rheumatoid arthritis	1946	0.26 (0.39)	0.02-1.00	(reference category)	-		
Systemic lupus erythematosus	642	0.58 (0.27)	0.05-1.00	0.78	< 0.001		
Systemic sclerosis	433	0.69 (0.35)	0.04-1.00	0.79 0.74 Protection	< 0.001		
Vasculitis	362	0.71 (0.30)	0.04-1.00	0.74	< 0.001		

<sup>&</sup>lt;sup>a</sup>Lower SAPI scores equate to articles ordered at the front of issues, while higher SAPI scores equate to articles ordered at the end of issues.



Supplementary Figure 1. Box plots showing differences in standardised article placement indices (SAPI) for first author gender (A.), senior author gender (B.), industry funding (C.), first author's geographic region of affiliated institution (D.), research design (E) and disease category (F.)